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ABSTRACT
While studies have indicated that squamous cell carcinoma of the head and
neck (HNSCC) is associated with immune suppression, these studies did not analyze
the immune response at the dysplastic stage. This study utilized a mouse model of
4-nitroquinoline 1-oxide (4NQO)-induced oral carcinogenesis to examine the
alterations in immune phenotype at the premalignant and malignant stages of
HNSCC. Cervical lymph nodes of HNSCC-bearing mice were found to contain a
greater number of cells, including a greater number of conventional (Tconv) and
regulatory (Treg) T cells, compared to lymph nodes of control and premalignant
lesion-bearing mice. Premalignant lesion-bearing mouse lymph nodes consist of a
greater percentage of Tconv cells expressing markers for activation, memory, and
exhaustion compared to both control and HNSCC-bearing mice. Lymph nodes from
both premalignant lesion-bearing and HNSCC-bearing mice include increased
numbers ofThl, Tcl and Th17 cells compared to control mice. The data show that
while there is the expected increase in Tregs in lymph nodes when HNSCC is
present, there is also an unexpected increase in immune populations usually
associated with a beneficial anti-tumor response. In addition, the results
demonstrate that the premalignant stage of HNSCC development is associated with
a robust immune response involving an increase in inflammatory cells.
The use of dendritic cell (DC) vaccines as treatment for malignancy is
complicated by the immune evasion tactics often employed by carcinomas such as
HNSCC. This study aims to determine if an immune response can be elicited by
administering a DC vaccine during the premalignant stages of HNSCC, prior to

ix

Premalignant Oral Lesion Immunobiology: Immune Modulation and Vaccination

development of immune escape. Bone marrow-derived DCs were pulsed with
premalignant lesion lysate (OCpm) and administered to 4NQO-treated mice
exhibiting premalignant lesions. Endoscopic examination revealed that DCpm
vaccination and control vaccination with dendritic cells pulsed with normal tongue
epithelium lysate (Dent) significantly decreased lesion burden. Analysis of lymph
node cells revealed that while Dent vaccination resulted in a rapid increase in total
lymphocyte count, levels of activated Tconv cells, and Thl, Tel, Th17, Tcl7, and Th2
cells, DCpm vaccination results in a delayed, yet substantial, increase in these
immune effector mechanisms. This suggests that dendritic cell vaccination may
have a beneficial effect on clinical outcome regardless of type of antigenic
stimulation, and DCs pulsed with premalignant lysate rather than normal tongue
epithelium lysate result in a delayed immune effector response upon vaccination of
premalignant lesion-bearing mice.

x
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CHAPTER 1: IMMUNOEDITING AND HNSCC
1.1 An Introduction to Immunoediting
1.1.1 Elimination and Equilibrium

The classic theory of immunoediting describes the incredibly complex
immune interactions with dysplastic tissue during and after the development of
cancers. In the first stage of immunoediting known as elimination, immune cells
patrol the body, recognizing transformed cells and eliminating them through a
reaction that traditionally is described as involving Thl cells which direct CD8+
cytotoxic T cells (CTLs) and macro phages to clear the dysplastic tissue (1, 2).
Evidence for this inc,ludes research showing that mice with either severe-combined
immune-deficiency (SCID) or lack of recombination activating gene (RAG-I-), leading
to absence of T cells, B cells, and NK cells . are more susceptible to chemicallyinduced tumors than wild type (WT) controls (1 . 3, 4). Humans with
immunodeficiencies are also at an increased risk for carcinogenesis, whether the
cancers are of a viral or non-viral etiology (5-9). The type 1 response was identified
as the main effector mechanism of tumor immunosurveillance after it was found
that mice with specific deletions of CD4+ and/or CD8+ cells, antibody-mediated
neutralization or knockout of IFN-y, or knockout of IL-12 . perforin or TRAIL all have
increased incidence and/or growth of several different types of cancer (2, 10-16).
Despite the evidence for beneficial immune responses against dysplastic
tissue . sometimes the tissue is not sufficiently cleared. If the initial transformation
results in weakly immunogenic tissue, then it may avoid detection, moving into the
equilibrium phase of immunoediting. During this stage, immunogenic variants that

Chapter 1

2

Immunoediting and HNSCC

Premalignant Oral Lesion Immunobiology: Immune Modulation and Vaccination

arise may be targeted and eliminated by the immune system, while less
immunogenic variants that develop mutations making them more resistant to
immune effector mechanisms survive to multiply. In effect, the combination of time
and the selective pressure of the immune system on cells that are prone to
accumulate mutations to a greater degree than healthy cells results in the
emergence of tumor variants that have been shaped to completely avoid elimination
by the immune system (17-19).

1.1.2 Immune Escape
Tumor variants emerging from the process of immune equilibrium lose all
immunogenicity and develop methods of manipulating the immune system for the
tumor's benefit. This last stage of immunoediting is referred to as escape.
Established tumors have been shown to avoid immune recognition through
downregulation of immunogenic markers and/or MHC class I molecules (20, 21).
Malignancies can also combat immune destruction by sabotaging an antitumor
immune response through direct and indirect upregulation of immunosuppressive
cells and downregulation of immunostimulatory cells.
As indicated before, a type I reaction, in which Thl cells initiate cell-based
immune responses involving various immune effectors, is considered necessary for
a beneficial anti-tumor immune response to occur. In tumor escape, tumors develop
the ability to downregulate the type I effector response and upregulate a type II
effector response which, while beneficial under certain conditions, is most often
associated with a poor prognosis in cancer patients. Interleukin-12 and IFN-y, both
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type I cytokines, have been found in reduced levels in multiple types of cancers (2224). Reduced IL-12 in cancer patients has been associated with reduced numbers of
CTLs, and reduced IFN-y has been shown to reduce induction of MHC class I and
class II and directly induce T cell anergy (25-27).
In contrast to type I cytokines, the type II cytokines IL-4, IL-I0, and

TGF-~

have all been shown to be upregulated in patients with many types of advanced
cancers (22-24, 28, 29). IL-4 directly inhibits Th1 cell differentiation,
downregulates IFN-y production, and upregulates the type II response (30-34). Like
IL-4, IL-10 downregulates IFN-y production (33). It has also been shown to reduce
IL-12 production, downregulate MHC surface expression, and induce tumorassociated T cell tolerance (35-38).

TGF-~

affects the immune system in multiple

ways: it has been shown to reduce differentiation, proliferation and functional
capacity of T cells, including downregulation of a Thl response by inhibition of IL-2
and IFN-y production in Thl cells and inhibition of FAS ligand and perforin
expression in CTLs (39-45).

TGF-~

also inhibits costimulation, antigen presentation,

maturation, and IL-12 production in antigen presenting cells, further
downregulating a type I response (46, 47). Finally,

TGF-~

has been shown to

increase tumor production of prostaglandin E2 (PGE2) and vascular endothelial
growth factor (VEGF), which both promote tumor growth in multiple ways
themselves (48-51). These changes in the cytokine milieu contribute a great deal to
the blockade of a functional antitumor immune response in the microenvironment
of many established tumors.
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Many cancer types are also associated with an upregulation of
immunosuppressive cells such as CD34+ progenitor cells, myeloid-derived
suppressor cells (MDSCs), tumor associated macrophages (TAMs), and regulatory T
cells (Tregs). The CD34+ progenitor cell refers to the earliest hematopOietic
progenitor cell found in the circulation; these cells are found in low numbers in
healthy individuals and in elevated numbers in both the circulation and tumor mass
of cancer patients (52-55). These cells have been found to suppress T cell
proliferation through the release

ofTGF-~

(56, 57). MDSCs are less immature

progenitor cells from the same lineage as C034+ progenitors; they too have been
found to be elevated in various tissues of tumor-bearers, and their presence is
associated with a poorer prognosis (58-60). These cells have been shown to directly
suppress T cell responses and promote T cell apoptosis through production of ARGl
and nitric oxide synthase and indirectly suppress T cell responses through
production

ofTGF-~

and IL-I0 (61-64). TAMs are mature myeloid cells that

originated as circulating monocytes and have differentiated into type II
macrophages in the tumor microenvironment. Like C034+ progenitor cells and
MDSCs, they are upregulated in multiple tumor types and their upregulation is
associated with a poor prognosis (65-67). Also like MDSCs, TAMs suppress T cell
function through the production ofTGF-(3 and IL-10 (68-70). They also produce
several growth factors, such as epithelial growth factor, platelet-derived growth
factor, and basic fibroblast growth factor that can directly promote tumor growth
(71, 72). Both CD34+ progenitor cells and MDSCs appear to be mobilized from the
bone marrow and recruited to the site of the tumor by a combination of tumor-
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derived GM-CSF and VEGF (73-77). TAM differentiation is thought to be a result of
the elevated levels of Type II cytokines such as IL-4, IL-6, IL-l0, IL-13, PGE2, and
TGF-(3 in the tumor microenvironment, factors that also may contribute to MDSC
mobilization (77-83).
Tregs are a heterogeneous population of either naturally-occurring or
inducible T cells expressing the transcription factor forkhead box protein 3 (Foxp3)
that act to suppress immune function and promote tolerance (84-86). Many of these
cells also express the surface marker ofT cell activation, CD25 (87). Elevated
numbers ofTregs are found in the tumor microenvironment and periphery in
multiple cancer types, and they most often correlate with a poor prognosis (88-96).
Tregs suppress immune function through contact-dependent mechanisms, such as
through membrane-bound

TGF-~,

CTLA-4 binding to B7 on target T cells or

dendritic cells, and expression of FAS ligand or granzyme B, or through contactindependent mechanisms, such as through secretion of IL-l0, TGF-(3, and IL-4 (87,
97-101). Depletion of Tregs . through the use of antibodies targeting CD25 or
antibodies targeting CTLA-4, has been shown to be beneficial in promoting tumor
rejection (102-104).

1.1.3 Inflammation as a Tumor-Promoting Mechanism
Despite the increasing understanding of the traditional role of the immune
system during tumor immunoediting, the role of the immune system during the
development of cancer has proven to be much more complicated than previously
thought. While directed inflammation in the form of a specific type I immune
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response may help to eliminate growing and established tumors, unresolved chronic
inflammation often serves to promote tumorigenesis. Around 20% of cancers are
associated with chronic infections, such as Helicobacter pylori infection of the
stomach and hepatitis B or C viral infection of the liver. while around 30% of
cancers are attributed to tobacco use and 20% of cancers are attributed to obesity,
both of which trigger chronic inflammation which has been linked to their tumorpromoting effects (105-110). The autoimmune conditions ulcerative colitis and
Crohn's disease greatly increase the risk for intestinal cancers (111). In addition,
use of anti-inflammatory agents such as COX2 inhibitors has been shown to reduce
tumor incidence, especially for colon cancer, and possibly even help to reduce tumor
burden in patients with certain cancers, such as breast and ovarian cancer, when
used in combination with current treatment modalities (112-114). However,
chronic inflammatory conditions such as rheumatoid arthritis and psoriasis do not
increase the risk of cancers of the joints or skin (llS). It is not well understood
why chronic inflammation in some locations can contribute to cancer risk, while
chronic inflammation in other locations does not.
While the relationship between tumor-promoting inflammation and
antitumor immune responses is not fully elucidated, researchers have been able to
identify inflammatory immune effectors that may at times promote rather than
suppress tumorigenesis. As indicated above, a type II response has long been
associated with a more tumor-promoting than antitumor response, mainly due to
the downregulation of the type I response. However, type I responses have also
been shown to contribute to tumor growth. While M1 macrophages produce IL-12,
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helping to direct a Thl-type response, they are also responsible for the majority of
the production of tumor-promoting cytokines such as

IL-l~,

IL-6, and TNFa (116,

117). IL-l has been shown to be released in response to inhalation of asbestos or
silica particles or in response to necrotic cell death as seen in a tumor after
chemotherapeutic treatment or after the tumor's growth outpaces its blood supply,
and it has been linked to enhanced tumor progression in multiple models (118,
119). IL-6 and TNFa have been shown to not only enhance tumor progression but
also directly promote cancer cell growth and survival (117). Even IFN -y producing
Thl cells and CTLs have been implicated in contributing to tumor promotion,
progression, and metastasis in certain circumstances (120-122). Th17 cells have
been linked to an improved prognosis in several cancer types and shown to result in
a strong antitumor response when adoptively transferred into certain tumor models
(123-128). Conversely, they have been shown to be associated with a poorer
prognosis in patients with gastric cancer (129). Also, the main functions of the
cytokines produced by Th17 cells, IL-17 and IL-23, include intense inflammation,
angiogenesis, and possibly inhibition of effector CTL function, factors that promote
tumorigenesis (130-133).
While it would certainly be preferential for one to be able to place specific
immune effectors into the categories of IItumor-promoting" or anti-tumor," the role
Il

of the immune system during the initiation and development of cancer is in fact
much more complicated. The location, timing, duration, and intensity of the
immune response are integral to determining the impact of this response. These
factors and the overall balance of the various inflammatory and anti-inflammatory
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signals are what determine if conditions are favorable for oncogenesis or tumor
clearance. The elucidation of each of these individual factors in specific tumor types
is integral to the development of immunotherapeutic techniques to prevent or
combat those cancers.

1.2 Immune Reactivity Potential Toward UNSee
Head and neck squamous cell carcinomas (HNSCC) are aggressive
malignancies, and treatment options have traditionally involved surgery or, more
recently, also radiation plus chemotherapy. Despite advances in treatment options
and attempts at organ preservation, the success rate of treatment has not improved
significantly, and current treatments have typically resulted in debilitating effects
and reduced quality of life (134). An alternative or adjuvant treatment approach
being tested for various malignancies is immunotherapy, although studies testing
effectiveness of novel immunotherapeutic approaches for HNSCC are lagging.
As with other malignancies, the rationale for considering immunotherapy for
HNSCC is based on the expression of potentially immunogenic antigens that are
either selectively expressed on malignant versus normal tissues or expressed in
increased levels, or tumor-associated antigens (TAAs). These antigens include the
mucin MUC-1, epidermal growth factor receptor (EGFR), the RAGE and GAGE
families of tumor antigens, NY-ESO-l, and others (135-138). To increase the
effectiveness of immunotherapeutic strategies, efforts are underway to improve the
identification of candidate tumor antigens that cause T cell responses. One such
effort involves the use of a newly developed} automated, two-dimensional
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chromatography system PF20 that fractionates the proteome of human tumor
tissues (137). Advances in this area have the potential to reveal more immunogenic
proteins to target, leading to stronger and more enduring responses to therapy.
Immunotherapeutic approaches hinge on the ability of the immune system to
recognize these tumor antigens as foreign and develop a response, humoral and/or
cellular, against the malignant tissue. Patients with HNSCC have been shown to
mount antibody responses to antigens that are expressed on the tumor tissue.
Reactivity includes antibody responses to the mucin MUe-1, with increased serum
levels ofMUC-1 and antibodies to MUC-1 in patients with more advanced disease
and nodal involvement (139). Antibodies to p53, which is frequently mutated in
HNSCC, are also detectable in serum of HNSCC patients and are indicative of nodal
disease involvement (140).

In addition to humoral responses to HNSCC, patients

can mount cellular immune responses to the tumor. Increased intraepithelial C08+
tumor-infiltrating lymphocytes (TILs) in HNSCC metastases, as well as increased
numbers of CD20+ B cells in involved lymph nodes, are associated with a better
prognosis (141). Also, both C04+ and CD8+ T cells isolated from patients with
HNSCC can be activated in response to tumor antigens (137). Antigen processing
and cross-presentation by dendritic cells to C08+ T cells can stimulate their
reactivity to tumor antigens. Less well studied has been the potential ofy /0 T cells
to react to tumor. Recently, a subset ofy /S T cells expressing the NK cell-associated
molecule CDS6 has been shown to exhibit cytolytic reactivity to HNSCC (142).
These studies indicate that HNSCC is a good candidate for the development of
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immunotherapeutic approaches, as HNSCC expresses tumor antigens and the
immune system has the potential to react against these antigens.

1.3 HNSee-Induced Defects in Immune Function
1.3.1 Avoiding Immune Detection and Destruction

Despite the above-described potential reactivity toward tumor antigens,
these immune responses have not proven to be sufficient to prevent tumor
progression. This is likely due to the many mechanisms by which established
HNSCC tumors achieve immune escape. This includes the development of ways by
which tumors can avoid detection by the immune system or decrease vulnerability
to immune effector mechanisms. HNSCC cells have been found to decrease surface
expression of MHC class I molecules, thereby making them less susceptible to
detection by tumor specific CTLs (143-145). Further research shows that HNSCC
cells also downregulate surface expression of costimulatory B7 molecules that are
necessary for proper T cell signaling (146,147). HNSCC has also been shown to
avoid immune effector mechanisms by upregulation of surface expression of Fas
ligand and PD-L1, both of which can induce apoptosis in activated lymphocytes
(148,149).

1.3.2 UNSee-Derived Soluble Immune Inhibitory Mediators

Another way by which HNSCC tumors can achieve immune escape is through
the induction of profound immune suppression that is characteristic for HNSCC
patients. In fact . a prospective study analyzing risk factors for HNSCC patient
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survival showed that among the top 4 risk factors was the extent of immune
suppression of the HNSCC patients (150). The mechanisms of immune suppression
are multifocal. HNSCC produces several immune inhibitory factors including PGEz,
TGF-(3, VEGF, IL-6, and IL-I0 (151-153), mediators long known to be inhibitory
toward T-cell functions (154-156). The release ofTGF-[3 and PGEz from HNSCC has
been shown to correlate with reduced intratumorallevels of T -cells, in particular
CTLs (157). More recently, dendritic cells of HNSCC patients have been shown to be
defective in maturation and functionally impaired (158, 159). This impairment is
attributed in part to the production by HNSCC of VEGF, PGEz and TGF-[3. These
mediators induce a shift in dendritic cell cytokine production to contribute to a
more tolerogenic phenotype. They also alter expression of the chemokine receptors
that are important in allowing dendritic cell migration to tumor-draining lymph
nodes. In these studies, the dendritic cell dysfunction induced by HNSCC was
overcome by blocking PGE2 and TGF-f3. Investigation into additional strategies
aimed at diminishing or avoiding the effects of immune suppressive mediators
produced by HNSCC may help to enhance the effectiveness of immune stimulatory
treatment.

1.3.3 HNSee Induction of Immune Suppressive Cells

In addition to producing soluble mediators that inhibit immune reactivity of
HNSCC patients, HNSCC also induces immune inhibitory cells. The levels ofTreg
cells within HNSCC patients is greater than levels in healthy controls (160, 161). A
lower ratio of CTLs to Tregs is associated with decreased survival (162). In addition
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to secreting the immunosuppressive cytokines

TGF-~

and IL-l0, Tregs hydrolyze

ATP to a greater extent and, in turn, cause increased levels of adenosine-mediated
suppression of effector T cells. However, Bergmann found that Tregs in the
peripheral blood and tumor were elevated even further in patients with no evident
disease after oncologic therapy compared to patients with active disease, and
Badoual found that Treg infiltration into the tumor was actually associated with
improved locoregional control (163, 164). This association of Treg infiltration with
an improved prognosis may possibly be attributed to Treg-induced suppression of
tumor-associated cells producing inflammatory mediators, growth factors, and
angiogenic factors linked to promotion of advanced HNSCC tumors. This indicates
that the impact of elevated Treg levels in HNSCC may be more complicated than
previously believed.
Another immune suppressive cell that our laboratory has shown to be in
increased levels in the peripheral blood of HNSCC patients is the immature CD34+
progenitor cell. These cells are mobilized from the bone marrow by tumor-derived
GM-CSF and are chemoattracted into the tumor by VEGF. They mediate their
immune inhibitory activity by production ofTGF-(3 (55, 76,165,166). Depending on
the cytokine milieu, the tumor-mobilized CD34+ cells can differentiate into
granulocytes, monocytes or dendritic cells (55, 165, 167). Studies in animal tumor
models have shown that these cells can also differentiate into endothelial cells (52).
In order to alleviate the level of immune suppression in HNSCC patients, our studies
used the strategy of taking advantage of the immature status of these CD34+ cells
and driving the differentiation of these inhibitory cells into stimulatory dendritic
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cells. This was accomplished with treatment of HNSCC patients with the active
hormone 1,25-dihydroxyvitamin D3 (168, 169). Such a strategy not only resulted in
a decrease in levels of intratumoral CD34+ suppressor cells and an increase in
numbers of mature dendritic cells and T cells expressing markers of activation
within the HNSCC, but it also significantly prolonged the time between surgical
treatment and cancer recurrence. Others have shown that HNSCC CD34+ progenitor
cells are induced to produce increased levels of the immune inhibitory mediator,
IL-6 (170). These CD34+ cells are likely to be an earlier precursor within a spectrum
of immune inhibitory cells in various stages of differentiation that include MDSCs.
MDSCs, which are found in a multitude of tumor types including HNSCC, mediate
their immune suppressive activity mainly through the induction of reactive oxygen
species production (171). Their suppressive activity can be blocked by inhibiting
NADPH oxidase. A newly recognized tumor-induced immune suppressive
population that has been described for HNSCC patients is the immune inhibitory
endothelial cell (172). The suppressive activity of endothelial cells is induced by
tumor-derived VEGF. These HNSCC-induced immune inhibitory endothelial cells
mediate their immune suppressive activity through production of PGE2 which, in
turn, blocks T-cell proliferation, production of IFN-y, perforin and granzyme B,
suggesting inhibition of both T-cell helper and cytolytic functions. Blockade of VEGF
through the use of bevacizumab could potentially prevent the induction of both
CD34+ progenitor cell and suppressive endothelial cell populations.
Many studies have focused on determining the mechanisms by which
established HNSCC escapes an anti-tumor response. However, these studies are
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complicated by the complex nature of the relationship of the immune system with
cancer. It is clear that further investigation into the mechanisms by which HNSCC
manipulates the immune system and strategies to block or reverse the consequent
immune suppression may greatly assist the efficacy of attempts to stimulate
immune rejection of HNSCC. Investigation into the origin of these mechanisms by
examining the immune responses during HNSCC development may help in
understanding HNSCC-associated immune escape, and such research may uncover
potential therapeutic avenues by which one may target dysplastic tissue before
immunosuppression arises.
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CHAPTER 2: RATIONALE, HYPOTHESIS, AND SPECIFIC AIMS

2.1 Rationale

Tumor-induced immunosuppression is utilized by many solid malignancies
to avoid detection by the immune system as well as to avoid the effects of an antitumor immune response. However, many malignancies arise out of and even
promote smoldering inflammation concurrently with the induction of
immunosuppression. The promotion of oncogenesis versus tumor clearance
depends on a multitude of factors including the mediators involved . the location of
the tumor. and the intensity and timing of the response. Therefore, investigation
into each of these factors is necessary to determine the appropriate targets for
immunotherapeutic intervention to combat carcinogenesis.
HNSCC is a highly aggressive malignancy that has proven difficult to treat,
with a S-year survival rate of about 500/0, due in part to the many immune evasive
tactics employed by the tumor (28 . 150, 163, 164, 173-177). While many of the
aspects of immune escape utilized by HNSCC have been studied, some of the data
has been contradictory, such as the clinical implications of the increase in Tregs
seen in HNSCC (163). Development of oral HNSCC usually begins with the
appearance of thick adherent plaques, known as leukoplakias and erythroplakias, on
the floor of mouth, the lip, and the lateral tongue (173). Very little is known about
the immune response at the premalignant stages. One way to clarify the role of
immune effectors in established HNSCC is to investigate the immune responses
elicited during the early stages of dysplasia leading up to HNSCC. In addition,
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exposure of immune competency at the premalignant stage of HNSCC may provide
clinicians with an avenue of immunotherapeutic delivery that avoids the
complications of immunosuppression seen in established HNSCC.
Novel treatment approaches for HNSCC patients are essential due to the
minimal level of improvement in patient survival over the last few decades, and
immunotherapy could be a strong candidate for one such approach. However, some
approaches to actively stimulate immune reactivity have not lived up to
expectations in the past, likely due to the multitude of immune inhibitory
mechanisms that are induced by HNSCC (178, 179). It is possible that initiating
immunotherapy prior to the development of immune escape may prove more
successful at preventing the establishment of HNSCC. HNSCC is somewhat unique in
that it may be diagnosed in its premalignant stages. Also, HNSCC and oral
premalignant lesions have been shown to share overexpression of certain antigens
that may be utilized as markers to allow specific recognition of both types of tissues
by immune effectors (136, 180). Dendritic cell-based vaccines have been used in

multiple studies as a means to stimulate antitumor immune reactivity through the
use of primed, activated dendritic cells to activate tumor antigen-specific T cells
(181-185). The development of premalignant lesion antigen-pulsed dendritic cell
vaccines, administered at the premalignant stage of HNSCC, may be utilized to
stimulate protective immunity against further development of premalignant oral
lesions and progression to HNSCC.
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2.1.1 Hypothesis

"We hypothesize that the premalignant stage 0/ HNSCC
development will be associated with a local increase in inflammatory
immune effector mechanisms and lack a/immunosuppression while
established HNSCC will be associated with local and systemic
immunosuppression.

Furthermore~

we hypothesize that administration

of a premalignant lesion lysate-pulsed dendritic cell vaccine to mice
bearing premalignant lesions will induce immunity against development
of premalignant lesions and HNSCC."

2~1.2

Specific Aims

This hypothesis will be tested through the following specific aims:

Aim 1: To investigate the alterations in immune phenotype at the

premalignant and malignant stages of HNSCC within a 4NQO carcinogeninduced mouse model and in human patients.
While HNSCC is associated with widespread immune manipulation, it
is likely that this phenomenon has not yet developed or has developed to a
lesser degree at the premalignant stage. Aim 1 analyzes the immune
responses at the local and systemic levels in mice treated with the carcinogen
4NQO until the development of premalignant lesions or HNSCC and humans
with premalignant lesions or HNSCC.
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Aim 2: To use premalignant lesion-pulsed dendritic cells in vivo to skew

the immune phenotype within mice bearing premalignant lesions
towards imm unity against further development of premalignant oral
lesions and progression to HNSCC.
Initiation of immunotherapy at the premalignant stage of HNSCC may
have the increased success because of the avoidance of the widespread
immunosuppression seen in HNSCC. As both premalignant lesions and
HNSCC share overexpression of common tumor antigens, dendritic cell
vaccination using premalignant lesion lysate as an antigen source may be
able to promote an anti-tumor response. Aim 2 investigates if premalignant
lesion lysate-pulsed dendritic cell vaccination of mice bearing premalignant
lesions can stimulate protective immunity against the further development of
premalignant lesions and progression to HNSCC.

2.2 Significance

Many studies have explored the local and systemic immune evasive factors
employed by established HNSCC. However, it is still unclear what the roles of each
cell type are in the HNSCC microenvironment. In addition, this immunosuppression
has impeded attempts at the immunotherapeutic stimulation of an anti-tumor
response. A goal of this study is to further investigate the immune alterations in the
setting of HNSCC as well as to, for the first time, investigate the immune alterations
during the development of HNSCC. Not only will this help to understand the roles of
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the immune system in HNSCC, it will also help in identifying specific targets and
possible avenues for the development of immunotherapeutic techniques to either
prevent or treat HNSCC.
This study also aims to further explore the feasibility of using premalignant
lesion-pulsed dendritic cells as a preventative treatment for HNSCC, a disease that
presently has few effective treatments and a high mortality rate. Optimally, the
initiation of this treatment at the premalignant stage will allow for the development
of an effective anti-tumor response without the obstacle of the extensive
immunosuppression seen with HNSCC. This will ideally lead to the identification of
individual antigens in these tissue types responsible for eliciting immunity, allowing
for the development of an antigen-specific vaccine that could be applied to multiple
patients. The long-term goal is to use vaccination to prevent recurrence in patients
who have developed oral premalignant lesions and had them surgically removed, as
these patients would still have a high risk of developing more premalignant lesions
and HNSCC if left untreated.
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CHAPTER 3: IMMUNE RESPONSE TO HNSCC DEVELOPMENT

Aim 1: To investigate the alterations in immune phenotype at the premalignant

and malignant stages of HNSCC within a 4NQO carcinogen-induced mouse model
and in human patients.

3.1 Introduction
Head and neck squamous cell carcinoma (HNSCC) is an aggressive
malignancy that has proven quite difficult to treat. Despite advances in care over
the past 30 years, the five-year survival rate remains around 50% (173), with a fiveyear survival rate of 28% for patients with advanced HNSCC (186). In addition to
the high mortality rate, surgical treatment of advanced HNSCC is associated with
significant morbidity due to the major disfiguring consequences and functional
defects that can result (173, 186). However, this malignancy is somewhat unique in
that, with proper care and attention, it can be diagnosed in its premalignant stages
as white or red patches on the oral mucosa referred to as leukoplakias or
erythroplakias. If diagnosed at this stage, prognosis is conSiderably improved .
though another hallmark of oral premalignancy and HNSCC is a high likelihood of
recurrence (173). Therefore, our focus is shifting towards identifying this disease in
its premalignant stages and ultimately developing treatment strategies to halt
progression towards established HNSCC.
Multiple studies have indicated that HNSCC is associated with immune
suppression and manipulation, factors that may contribute to the tenacity of this
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disease. Patients with acquired or iatrogenic immunodeficiencies have an increased
incidence of HNSCC (174, 175). HNSCC patients exhibit increased levels of
regulatory T cells (Tregs) (163, 164, 176) and C034+ progenitor cells (177), both
suppressive cell populations. Studies have identified skewing of the ThljTh2
balance within HNSCC patients to a Th2 dominant phenotype with decreased Thl
activity (28, 176), indicating tumor-induced manipulation of the environment to
prevent an effective anti-tumor response. However, while an increase in the CD34+
population is associated with a poor patient outcome (177l Treg infiltration into
the tumor was shown to be associated with improved locoregional control (164). In
addition, recent studies revealed that peripheral blood mononuclear cell (PBMC)
and tumor infiltrating Tregs are elevated even further in patients with no evident
disease after oncologic therapy compared to those with active disease (163).
Further complicating the matter is the fact that few to none of these studies
stratified by HPV status. HPV-positive HNSCC, representing a minority of cases, has
a more favorable prognosis compared to classic HPV-negative HNSCC, a
phenomenon which appears to be related to the differing immune response to
HPV( +) vs. HPV(-) disease (187). In fact, one study showing that CD3 hi gh tumors
have decreased metastasis rates than CD3 low tumors found that their results only
held for HPV( +) tumors (188), indicating that conclusions drawn from previous
studies may be influenced by HPV status of study participants.
In addition to gaps associated with HNSCC etiology, little to no research thus
far has focused on investigating the immune status at the premalignant stage of
HNSCC carcinogenesis. One study showed that expression of Fas, a death receptor
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that renders a cell susceptible to immune-induced apoptosis through binding with
its ligand (FasL), and expression of FasL itself were increased significantly in human
oral premalignant tissue compared to normal control. While Fas levels in malignant
tissue decreased to below control levels, levels of FasL continued to rise in
malignant tissue compared to premalignant tissue, a phenomenon associated with
immune escape as tumor-associated FasL can trigger apoptosis of infiltrating
lymphocytes (189, 190). Though these results indicate that a significant immune
response may take place in dysplastic oral tissue, no further studies into this topic
have been carried out. Consequently, research into the immune response during
and after the development of HPV-unrelated HNSCC is necessary in order to gain
greater insight into possible future immunotherapeutic techniques that may be
utilized to prevent or reverse HNSCC progression.
The present study investigates the proportions and total numbers of specific
populations of immune cell types within cervical lymph nodes of control mice and
mice bearing oral premalignant lesions or HNSCC, using a model of 4-nitroquinoline
i-oxide (4NQO)-induced carcinogenesis (191). While there are multiple models
that may be used to study HNSCC, such as the HPV( +) cancer model (192) and the
orthotopic SCC VII syngeneic tumor system (193), we chose to use this model of
4NQO-induced carcinogenesiS because it allowed the study of HPV( -) disease versus
HPV( +) disease, which has a significantly better prognosis (194), and it permitted
the analysis of the immune response during the gradual progression to HNSCC
rather than the immune response to injection of malignant cells. In addition, 4NQO
mimics the carcinogenic effects of tobacco, the highest risk factor for HNSCC (173,
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191). As tongue epithelium was determined to contain very low numbers ofT cells

and immune responses are most often orchestrated in draining lymph nodes,
analysis focused on the cervical lymph nodes. Lymph nodes were analyzed to
evaluate immune cell makeup of response . and tongue epithelium was lysed to
determine presence of various cytokines. Due to trends reported in the literature. it
was hypothesized that development of HNSCC would be associated with a gradual
increase in immunosuppressive populations such as regulatory T cells and Th2 cells
and a decrease in Thl and Tel cell populations. While the current study verifies
that HNSCC-bearing mice exhibit an increase in Treg populations, it is also revealed
that the presence of HNSCC is associated with an increase in activated conventional
CD4+ and C08+ T cell populations, including an increase in Thl and Tcl cells that is
not accompanied by an increase in Th2 cells. In addition, it was determined that the
premalignant stage is associated with an increase in the percentage of activated and
memory conventional T cells, as well as an increase in the percentage ofThl and
Tel cells compared to control and an increase in the percentage ofTh17 cells
compared to control and HNSCC-bearing mice.
Human samples were also tested for cytokine levels as a preliminary
indicator of immune status. Normal/adjacent tongue tissue . premalignant tissue,
and tumor tissue were obtained from human patients. Peripheral blood was also
collected from unaffected individuals, premalignant lesion-bearing individuals, and
HNSCC patients. Cytokine bead array analysis of tissue lysate and peripheral blood
revealed a similar trend as what was detected in mice: while the expected local
increase in IL-l0 in HNSCC tissue was observed, there was also a local increase in
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IFN-y in HNSCC tissue compared to normal/adjacent tissue. In addition . analysis
showed an impressive increase in the Thl cytokines IFN-y and IL-2 and the Th17
cytokine IL-17 A in human premalignant tissue compared to both normal/adjacent
and HNSCC tissue.
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3.2 Materials and Methods
Oral HNSCC carCinogenesis

Five mg/ml 4NQO was administered in propylene glycol stock in the drinking
water (diluted to SO llg/ml) of 2 month old (at start) female CS7BL/6 mice (Charles
Rivers Laboratory, Wilmington, MA) until development of premalignant oral lesions
(6-8 weeks) or HNSCC (12-16 weeks). Control mice received propylene glycol
diluent. To monitor development of premalignant oral lesions and HNSCC, oral
cavities of 4NQO-treated mice were endoscoped weekly using a Stryker 1.9mm x
30° scope and a Stryker 1088 HD camera. Mice were sedated with inhaled isoflurane
(Piramal Healthcare, Mumbai, India) during the procedure.

Cervical lymph node processing

Cervical lymph nodes were harvested from C57BL/6 mice and homogenized
via a Stomacher 80 homogenizer (Seward, West Sussex, UK) set on high for 90 sec.
Cells were passed through a 40-llm cell strainer (BD Falcon, San Jose . CA) and rinsed
with Hank's Buffered Saline Solution (HBSS, Invitrogen, Carlsbad, CA) to remove
debris. Cells number was determined by counting cells excluding trypan blue using
a hemocytometer.

Human samples

Recruitment of patients into this study was approved by the Institutional
Review Board of record. Peripheral blood samples and tissue samples were
collected from patients bearing premalignant lesions or HNSCC, and surgically
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excised HNSCC and premalignant tissues were cryopreserved at -80 0 C until used for
cytokine analyses. HNSCC tissues from untreated patients were also obtained from
the Medical University of South Carolina Tissue Biorepository. Normal, noncarcinogenic oral tissue was procured from the adjacent areas bordering oral cancer
tissue . and these tissues were deemed pathologically normal with no microscopic
evidence of invasive carcinogenic disease.

Flow cytometric analysis o/surface markers and Foxp3 expression
All reagents in this section were from BO Biosciences (San Jose . CA) unless
otherwise specified. In order to detect levels of C08 and CD4 positive cells in
relation to Foxp3 and CDllb+Gr-l + MOSes, ex vivo cervical lymph node cells in
single-cell suspension were washed once in Stain Buffer and resuspended at 1x10 7
cells/ml. Nonspecific staining of a total of lxl0 6 cells was blocked with FBS and
anti-CD16/32 monoclonal antibody prior to cell surface staining with the following
antibodies: PerCP-CyS.S CD4 . FITC CD8a, PE Gr-1, PE CD2S, PE PD-1, APC CD11b,
APC CD44, APe CD69, and APC KLRGl (eBioscience, San Diego, CA). Intracellular
staining for PE-Cy7 Foxp3 (eBioscience, San Diego, CA) was performed after fixation
with Foxp3 Fixation Buffer and permeabilization with Foxp3 Permeabilization
Buffer. Extent and frequency of positively stained cells was visualized using flow
cytometry (FACSCanto . San Jose, CA).

Flow cytometric analYSis of cytokine expression
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All reagents in this section were from BD Biosciences (San Jose, CA) unless
otherwise specified. In order to detect intracell ular cytokines, single-cell
suspensions of cervical lymph node cells were restimulated for 4 hours at 37°C with
50 ng/ml phorbol 12-myristate 12-acetate (PMA), 1 Ilg/ml ionomycin, and
brefelden A solution.

Nonspecific staining of total of lxl0 6 cells was blocked with

FBS and anti-CD16/32 monoclonal antibody prior to cell surface staining with the
following antibodies: PerCP-Cy5.S CD4 and PE-Cy7 CDBa. Intracellular staining for
PE IL-17 A, FITC IFN-y, APe IL-4, APC IL-I0 and Alexa Fluor 488 IL-13 (eBioscience,
San Diego, CA) was performed after fixation/permeabilization with
Cytofix/Cytoperm. Extent and frequency of positively stained cells was visualized
using flow cytometry (FACSCanto, San Jose, CA).

Cytokine bead array
All reagents in this section were from BD Biosciences (San Jose, CA) unless
otherwise specified. In order to detect cytokines released into supernatant, singlecell suspensions of cervical lymph node cells were restimulated for 4 hours at 37°C
with SO ng/ml PMA and 1 I-lg/ml ionomycin without addition of brefeldin A. In
order to detect cytokine levels in tongue tissue, mouse tongue epithelium was
obtained after incubation of tongue fragments with Dispase II (Roche, Florence, SC).
Both mouse and human tissue was lysed through sonication, protein concentration
was determined by BCA protein assay (Pierce, Rockford, IL) per manufacturer's
instructions, and final cytokine levels in tissue were normalized to pg/l00Jlg of
protein. Levels of IFN-y, IL-2, IL-17 A, IL-4, and IL-I0 in cell supernatant or tongue
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epithelium lysate were determined using a mouse cytometric bead array
ThljTh2jTh 17 cytokine kit. while levels of RANTES, MIP-1u, MIP-1f3, and IL-13 in
cell supernatant or mouse tongue epithelium lysate were determined using
cytometric bead array flex sets for the individual cytokines according to the
manufacturer's instructions. Relative amounts of each cytokine were analyzed
using FCAP Array software (San Jose, CA).

T cell purification and functional assays
CD4+CD2S- conventional T cells and CD4+CD2S+ regulatory T cells were
purified from mouse cervical lymph nodes using Dynabeads FlowComp Mouse
CD4+CD25+ Treg Cell Isolation Kit (Invitrogen . Carlsbad, CA). To measure T cell
proliferative response, CD4+CD25- Teonv cells from control, premalignant lesionbearing, and HNSCC-bearing mouse lymph nodes were labeled with CFSE using the
CellTrace CFSE Cell Proliferation Kit (Invitrogen, Carlsbad, CA) and cultured for 3
days in the presence of Dynabeads Mouse T -Activatory anti-CD3janti-CD28 beads
(Invitrogen . Carlsbad, CA). To measure T cell suppression. CFSE-Iabeled control
CD4+CD25- Tconv cells were incubated for 3 days with control, premalignant lesionbearing mouse, and HNSCC-bearing mouse CD4+CD25+ Treg cells at a 1:1 ratio with
anti-CD3janti-CD28 beads. Cell proliferation was measured by percentage of cells
with diluted CFSE.
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Statistical analysis
Data were reported using the mean as a measure of central tendency ±
standard error of the mean. To compare one variable condition between groups, the
2-tailed Student's t-test or Mann-Whitney U test was used. Significance was
reported in the 95 0/0 confidence interval.
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3.3 Results

Increase in absolute number of cervical lymph node cells in mice bearing HNSCC
compared to control mice and mice bearing premalignant oral lesions
Draining regional lymph nodes may become hyperplastic during the
development and progression of malignancy due to reactive lymphadenopathy,
metastasis, or both (195). To determine if draining lymph nodes undergo
hyperplasia during the premalignant stage or malignant stage of HNSCC
development, cervical lymph nodes from control mice, premalignant oral lesionbearing mice, and HNSCC-bearing mice were processed to single cell suspension,
and the number of try pan-blue excluding cells were counted. While mice bearing
premalignant oral lesions exhibit equal numbers of cervical lymph node cells as
control mice (4.94 x l0 6 ± 6.2Sx10s vs. 5.31x106 ± 7.29xl0s . p

= 0.362) . mice bearing

HNSCC exhibit a marked increase in number of cervical lymph node cells to more
than double the number found in control mice (1.17xl07 ± 2.63x106 vs. 5.31xl06 ±
7.29xl0 s, p = 0.006). This indicates that draining lymph node hyperplasia occurs to

a great extent after establishment of HNSCC but not during premalignant stages of
HNSCC development.

Increase in total number of conventional and regulatory lymphocytes in cervical lymph
nodes o/mice bearing HNSCC compared to control mice and mice bearing
premalignant oral lesions
Many solid carcinomas, including HNSCC . have classically been associated
with immunosuppression involving decreased conventional (Foxp3-) T cells and
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increased regulatory (Foxp3+) T cells and myeloid derived suppressor cells (MDSC),
contributing to immune escape (163, 164, 176). The upregulation of a conventional
T cell response is typically a goal of antitumor immunotherapy. While CD8+
cytotoxic T cells have long been considered to be the most beneficial in actively
combatting tumorigenesis through cytotoxic activity, recently CD4+ conventional T
cells have recently been shown to exhibit cytolytic activity that is beneficial in
eradicating established tumors (196, 197). To determine the relative composition
of CD4+ and CD8+ conventional T cells and regulatory T cells, as well as MDSCs, in
cervical lymph nodes of control, premalignant lesion-bearing mice} and HNSCCbearing mice, lymph node cells were stained for surface expression of CD4} CD8,
CDi1b, and Gr-l and intracellular expression of the regulatory T cell marker Foxp3.
Proportions of populations expressing each marker were determined through flow
cytometric analysis of stained cells (Fig 3.1a and b J. while total numbers of
populations expressing each marker (Fig 3.1c) were determined by multiplying the
percent positive by the number of lymph node cells for each individual mouse.
While no differences in CD11b+Gr-1 + MDSCs were observed among the three groups
(data not shown), HNSCC-bearing mouse lymph nodes consist of a greater total
number of conventional helper (CD4+Foxp3-) and cytotoxic (CD8+Foxp3-) T cells and
CD8+Foxp3+ regulatory T cells as well as a greater proportion and total number of
CD4+Foxp3+ regulatory T cells compared to both control and premalignant lesionbearing mouse lymph nodes (Fig 3.1b and c). This indicates that establishment of
HNSCC is associated not only with increased regulatory T cell levels but also with
increased numbers of conventional CD4+ and CD8+ T cells.
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Ratios of conventional to regulatory T cells were determined by dividing
number of CD4+Foxp3- or CD8+Foxp3- conventional T cells by number of
CD4+Foxp3+ or CD8+Foxp3+ regulatory T cells for each individual mouse. As shown
in Fig ld} while there is no significant difference between CD8+
conventional:regulatory T cell ratio between the three groups, both premalignant
lesion-bearing mice and HNSCC-bearing mice have a CD4+ conventional:regulatory T
cell ratio that is significantly lower than control. This suggests that while lymph
node cells from HNSCC-bearing mice exhibit large changes in numbers of both
conventional and regulatory CD4+ T cells . the relative degree of these changes
results in a relative proportion of these cells which is similar to the proportion
resulting from the minor decrease in CD4+ conventional T cells and minor increase
in CD4+ regulatory T cells seen in lymph nodes of premalignant lesion-bearing mice.

Decrease in proliferation of conventional T cells from HNSCC-bearing mouse lymph
nodes in response to stimulation compared to control.
Due to the unexpected increase in total number of conventional T cells in
mice bearing HNSCC compared to control mice . the proliferative capacity of these
cells in response to stimulation was evaluated. Conventional CD4+CD2S- T cells
were isolated from control, premalignant lesion-bearing} and HNSCC-bearing mouse
lymph nodes by magnetic isolation, stained with CFSE . and cultured for 3 days with
or without anti-CD3 and anti-CD28. Conventional CD4 cells from HNSCC bearing
mice had a significantly decreased percentage of proliferation compared to control
mice (Figure 3.1e). This was supported by cytokine analysis of cell supernatant
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which revealed a decrease in IL-2 released into the supernatant of HNSCC-bearing
mouse conventional CD4 cells compared to control conventional CD4 cells (Figure
3.1f). The levels of CD4+CD25- conventional T cell proliferation and IL-2 release at
the premalignant stage fell in the middle of levels for control cells and HNSCCbearing mouse cells.
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Fig 3.1 Established HNSee is associated with an increase in numbers of
regulatory and conventional T cells in cervical lymph nodes of affected mice
Representative results (a) and graphical representation (b) of flow cytometric
staining of cervical lymph node cells from control, premalignant lesion-bearing
(PM), and HNSCC-bearing mice (HNSCC) with at least 3 mice per group. *, p < O.OS.
Total numbers of populations (c) were determined by multiplying the percent
positive by the number of cervical lymph node cells for each individual mouse. *, p
< O.OS. **, P < 0.01. ***, P < 0.001. The CD4+ conventional T cell to regulatory T cell
ratio of both premalignant lesion-bearing and HNSCC-bearing mice is significantly
decreased compared to control Cd). *j p < 0.05. Representative results and
graphical representation (e) of flow cytometric analysis of CFSE-stained CD4+CD2sconventional T cells from control, premalignant lesion-bearing mouse, and HNSCCbearing mouse lymph nodes (at least 3 mice per group) after three days culture
with no stimulation (unstim) or stimulation with anti-CD3/anti-CD28 beads (stirn).
Cell proliferation was measured by percentage of cells with diluted CFSE. *, P <
0.05. Cytometric bead array analysis (t) of CD4+CD2s- conventional T cell
supernatant. *, p < 0.05. Representative results and graphical representation (g) of
flow cytometric analysis of CFSE-stained control CD4+CD2S- conventional T cells
after coincubation at a 1:1 ratio for three days with control mouse, premalignant
lesion-bearing mouse, or HNSCC-bearing mouse (at least 3 mice per group)
CD4+CD2S+ regulatory T cells in the presence of anti-CD3/anti-CD28 beads. *} p <
0.05.

Decrease in suppressive capacity of regula tory T cells from HNSCC-bearing mouse
lymph nodes compared to control regulatory T cells.
As it was counterintuitive to observe a simultaneous increase in both
conventional and regulatory T cells in the HNSCC-bearing mouse lymph nodes} the
suppressive function of the regulatory T cells was investigated. Magnetically
isolated control, premalignant-bearing, and HNSCC-bearing mouse lymph node
CD4+CD2s+ regulatory T cells were co-incubated with CFSE-stained control
CD4+CD2s- conventional T cells at a 1:1 ratio for 3 days in the presence of anti-CD3
and anti-CD28. As seen in Figure 3.1g, HNSCC-bearing mouse regulatory T cells
were found to be significantly less suppressive of control conventional T cells
compared to control mouse regulatory T cells, and the premalignant lesion-bearing
mouse regulatory T cells suppressed control Tconv cells at a level that was
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intermediate between control and HNSCC-bearing mouse Tregs. This indicates that
while Tregs increase in number during HNSCC development, these cells may also
lose their ability to inhibit conventional T cell proliferation.

Increased percentage of lymphocytes expressing markers for

activation~ memory~

and

exhaustion in cervical lymph nodes o/mice bearing premalignant oral lesions
compared to both control mice and mice bearing HNSCC
An optimal antitumor response depends on the activation, expansion and
survival of memory T cells. Suboptimal immune responses involve increased
numbers of T cells expressing markers of exhaustion (198, 199). To determine the
make-up of these phenotypic subsets between cervical lymph node cells from
control, premalignant lesion-bearing mice and HNSCC-bearing mice, CD4+Foxp3helper T cells and CD8+Foxp3- cytotoxic T cells were analyzed for expression of the
activation markers C025 and CD69, the marker of antigen experience, CD44, and the
exhaustion markers PD-l and KLRG1. As shown in Fig 3.2a and b, lymph node cells
from premalignant lesion-bearing mice exhibit a nearly 4-fold increase in percent of
CD25+ helper T cells compared to control and a nearly doubled percentage of C025+
helper T cells compared to HNSCC-bearing mice. HNSCC-bearing mice show a
significant but minor increase in percent of CD25+ cytotoxic T cells compared to
control. When factoring in total number of positive cells, while premalignant lesionbearing mice maintain an increased number of CD2S+ helper T cells compared to
control, HNSCC-bearing mice have an increased number of CD25+ and CD69+ helper
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and cytotoxic T cells compared to both control and premalignant lesion-bearing
mice due to the increase in overall cellularity (Fig 3.2c).
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Fig 3.2 Premalignant lesion-bearing mouse and UNSee-bearing mouse
cervical lymph nodes exhibit an increase in activated conventional T cells
compared to control mouse cervical lymph nodes
Representative results (a) and graphical representation (b) of flow cytometric
analysis of cervical lymph node cells from control, premalignant lesion-bearing
(PM), and HNSCC-bearing mice (HNSCC) with at least 3 mice per group. *, p < O.OS.
***, P < 0.001. Total numbers of populations (c) were determined by multiplying
percent positive by number of cervical lymph node cells for each individual mouse.
*, p < O.OS. **, P < 0.01. ***, P < 0.001.
Increased expression of the surface marker CD44 is used to distinguish T
cells with antigen experience from those that are naIve (200, 201). Analysis of
expression of the T cell memory marker C044 reveals that lymph nodes of mice
bearing premalignant oral lesions consist of a greater percentage of C044 hi gh helper

T cells compared to control and a greater percentage of C044 hi gh cytotoxic T cells
compared to both control and HNSCC-bearing mice (Fig 3.3a and b). However,
HNSCC-bearing mouse lymph nodes have a greater total number of C044 hi gh helper
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T cells compared to both control and premalignant lesion-bearing mice and a
greater number of CD44 hi gh cytotoxic T cells compared to controls, again due to an
increase in overall lymph node cellularity.
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Fig 3.3 Premalignant lesion-bearing mouse cervical lymph nodes consist of a
greater percentage of CD44 hi g h memory conventional T cells compared to
control and UNSCC-bearing mice
Representative results (a) and graphical represen tation (b) of flow cytometric
analysis of cervical lymph node cells from control, premalignant lesion-bearing
(PM), and HNSCC-bearing mice (HNSCC) with at least 3 mice per group. *, p < O.OS.
**, P < 0.01. Total numbers of populations (c) were determined by multiplying
percent positive by number of cervical lymph node cells for each individual mouse.
**, p < 0.01. ***, P < 0.001.
Expression of the markers PD-l or KLRG 1 indicates that a T cell has been
activated yet is at the point in its lifespan where, upon further stimulation, it will
undergo programmed cell death rather than perform effector functions (199, 202).
As such, these markers are often used to indicate T cell exhaustion. Analysis of
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expression of PD-l and KLRGl on conventional T cells in the lymph nodes of control,
premalignant lesion-bearing and HNSCC-bearing mice revealed that premalignant
lesion-bearing mice have a significant but minor increase in percent of KLRGl +
helper T cells compared to both control and HNSCC-bearing mice, while HNSCCbearing mice have a decreased percentage of KLRGI + helper T cells compared to
control as well (Fig 3.4a and b). When comparing total numbers of positive cells
(Fig 3.4c), HNSCC-bearing mouse lymph nodes consist of a greater number of PD-l +
helper and cytotoxic T cells compared to both control and premalignant lesionbearing mice. Taken together, this data indicates that the premalignant stage of
HNSCC development is associated with an increase in activated, memory
conventional T cells, some of which become exhausted, compared to control and
HNSCC-bearing mice. When it comes to total number of positive cells, however, the
prominent increase in cervical lymph node cellularity in mice with established
HNSCC makes it appear as though there is an increase in activated, memory and
exhausted T cells at this stage compared to the premalignant stage and control.

Cervical lymph nodes o/premalignant oral lesion-bearing and HNSCC-bearing mice
exhibit an increase in percent and total number of Thl, Tcl and Th17 cells as well as
an increase in secretion ofThl, Tel and Th17-related cytokines and chemokines
compared to control
To investigate the degree of upregulation or downregulation of different
subtypes of cytokine-secreting effector T cells during the progression to HNSCC,
cervical lymph node cells from control mice . premalignant lesion-bearing mice, and
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Fig 3.4 Premalignant lesion-bearing mouse cervical lymph nodes contain an
increased percentage of KLRG 1 + helper T cells, while UNSee-bearing mouse
cervical lymph nodes contain a greater total number of PD-l + conventional T
cells
Representative results (a) and graphical representation (b) of flow cytometric
analysis of cervical lymph node cells from control, premalignant lesion-bearing
(PM), and HNSCC-bearing mice (HNSCC) with at least 3 mice per group. *, p < O.OS.
**, P < 0.01. Total numbers of populations (c) were determined by multiplying
percent positive by number of cervical lymph node cells for each individual
mouse. *, p < O.OS. **, P < 0.01.
HNSCC-bearing mice were stimulated for four hours with PMA and Ionomycin with
or without brefeldin A. Cells incubated with brefeldin A were stained for CD4, CDS,
and the cytokines IFN-y, IL-17A, IL-13, IL-4, and IL-I0 and analyzed by flow
cytometry. Supernatants of cells incubated without brefeldin A and lysates of
tongue epithelium from each mouse group were analyzed by cytometric bead array
for presence of the Th 1 fTcl-related cytokines IFN -y and IL- 2 and chemokines
NTES, MIPl-u and

MIP-l~,

the Thl7-related cytokine IL-17A, and the Th2-related

cytokines IL-13, IL-6, IL-4, and IL-I0.
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An ideal antitumor immune response is often described as involving an
increased in Thl and Tel type immunity, and the upregulation of this population is
often considered a target goal of cancer immunotherapy (203). Many solid tumors,
including HNSCC, have been linked to a decrease in Thl immunity in past studies
(28 . 176). As shown in Fig 3.5a and b . premalignant lesion-bearing mice exhibit an
increase in percentage of lymph node cells staining double positive for CD4 and IFNy (Thl cells) and lymph node cells staining double positive for CDB and IFN-y (Tcl

cells) compared to controls. HNSCC-bearing mice have an even higher percentage of
Thl cells compared to both control and premalignant-lesion bearing mice and an
increased percentage of Tel cells compared to control alone. After factoring in total
number of lymph node cells (Fig 3.5c), premalignant lesion-bearing mice have a
greater number ofTcl cells compared to control} while HNSCC-bearing mice have a
greater number of both Thl and Tcl cells compared to control. Levels of secreted
cytokines and chemokines help confirm these results, as supernatants of cells from
both premalignant lesion-bearing and HNSCC-bearing mice contain increased IFN-y.
IL-2, RANTES, MIP-la and MIP-1P compared to control mice (Fig 3.Sd). While the
level of IL-2 in tongue epithelium lysate was lower in HNSCC-bearing mice
compared to control . the levels on IFN-y} RANTES, MIP-1a and MIP-lf3 were found
to be higher in premalignant epithelium lysate and HNSCC epithelium lysate
compared to control (Figure 3.Se). This data suggests that Thl and Tel immunity is
stimulated early in development of HNSCC . during the premalignant stages, and is
sustained even after HNSCC is established, contrary to what some previous studies
have indicated (28, 176).
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Fig 3.5 ThljTcl cells and related cytokines are increased in cervical lymph
nodes of premalignant lesion-bearing and HNSee-bearing mice
Representative results (a) and graphical representation (b) of flow cytometric
analysis of control, premalignant lesion-bearing mouse, and HNSCC-bearing mouse
cervical lymph node cells after stimulation for four hours with phorbol 12-myristate
13-acetate (PMA) and ionomycin in the presence of brefeldin A, with at least 9 mice
per group. *, p < 0.05. **, p < 0.01. Total numbers of populations (c) were determined
by multiplying percent positive by number of cervical lymph node cells for each
individual mouse. *, p < 0.05. Cytometric bead array analysis (d) of control,
premalignant lesion-bearing mouse, and HNSCC-bearing mouse cervical lymph node
cells after stimulation for four hours with PMA and ionomycin, with at least 9 mice
per group. *, p < 0.05. **, p < 0.01. Cytometric bead array analysis (e) of control,
premalignant lesion-bearing mouse, and HNSCC-bearing mouse tongue epithelium
lysate, with normalization to 100 \lg of protein (as determined by BCA protein assay),
with at least 10 mice per group. *, p < 0.05.
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The role of Thl7 cells in tumor immunology is less well defined than that of
Thl and Tcl cells. While populations ofTh17 cells have been shown to be expanded
in multiple cancer types, including HNSCC, the benefit and/or detriment of these
cells remains under debate (204, 20S). Both premalignant lesion-bearing and
HNSCC-bearing mouse lymph nodes contain a greater percentage (Fig 3.6a and b)
and number (Fig 3.6c) ofThl7 (CD4+IL-17 A+) cells compared to control mouse
lymph nodes, while premalignant lesion-bearing mouse lymph nodes contain a
greater percentage ofTh17 cells than HNSCC-bearing mouse cervical lymph nodes
(Fig 3.6a and b). This is supported by the cytometric bead array analysis showing a
greater amount of IL-l7 A released into the supernatant of premalignant lesionbearing mouse lymph node cells compared to control (Fig 3.6d). Levels of IL-17 A in
tongue epithelium lysate were too low to be detected by cytometric bead analysis.
This data indicates that development of premalignant lesions is associated with an
inflammatory immune response consisting ofTh1, Tel and Thl7 cells, and that
while the Thl response is sustained throughout HNSCC establishment and
progression, the Th 17 response wanes.
Among the many immune evasive mechanisms often employed by solid
malignancies, the skewing of a Th1-driven cell-mediated response into a less
effective Th2-driven humoral response has been described as occurring in the
setting of HNSCC (28, 176). The only significant difference among Th2 cytokines
identified by flow cytometric analysis of lymph node cells is a minor decrease in
percent of CD4+IL-13+ cells in lymph nodes of HNSCC-bearing mice compared to
premalignant lesion-bearing mice (Fig 3.7a and b). Of the Th2 cytokines measured
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Fig 3.6 Th17 cells are increased in cervical lymph nodes of premalignant
lesion-bearing and UNSee-bearing mice
Representative results (a) and graphical representation (b) of flow cytometric
analysis of control, premalignant lesion-bearing mouse, and HNSCC-bearing mouse
cervical lymph node cells after stimulation for four hours with phorbol 12-myristate
13-acetate (PMA) and ionomycin in the presence of brefeldin A, with at least 9 mice
per group. *, p < O.OS. ***, P < 0.001. Total numbers of populations (c) were
determined by multiplying percent positive by number of cervical lymph node cells
for each individual mouse. *, p < O.OS. **, P < 0.01. Cytometric bead array analysis (d)
of control, premalignant lesion-bearing mouse, and HNSCC-bearing mouse cervical
lymph node cells after stimulation for four hours with PMA and ionomycin, with at
least 9 mice per group. **, p < 0.01.
in supernatants, only a small decrease in level of IL-4 released from HNSCC-bearing
mouse lymph node cells compared to premalignant lesion-bearing mouse lymph
node cells was detected (Fig 3.7d). The measurement ofTh2 cytokines in tongue
epithelium lysate revealed no significant differences between the three mouse

Chapter 3

47

Immune Response to HNSCC Development

Premalignant Oral Lesion Immunobiology: Immune Modulation and Vaccination

groups (data not shown). This indicates that HNSCC development is not strongly
associated with any change in Th2 cytokines.
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Fig 3.7 No major changes in levels ofTh2 cells or cytokines between cervical
lymph nodes of control, premalignant lesion-bearing and HNSee-bearing
mice.
Representative results (a) and graphical representation (b) of flow cytometric
analysis of control, premalignant lesion-bearing mouse, and HNSCC-bearing mouse
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Human premalignant oral lesion tissue exhibits a dramatic increase in levels of IFN-y,
IL-2, and IL-17A compared to both normal/adjacent and HNSCC tissue, while human

HNSCC tissue exhibits a simultaneous increase in levels of IFN-y and IL-l 0 compared to
control tissue
To investigate the local levels ofTh1, Th17, and Th2 cytokines in humans,
normal/adjacent tongue tissue, premalignant tissue, and HNSCC tumor tissue was
obtained from patients, mechanically lysed, and analyzed by cytokine bead array for
the presence of the Th1 cytokines IFN -y and IL-2, the Th17 cytokine IL-17 A, and the
Th2 cytokines IL-4 and IL-10 (Fig 3.8a). Levels of cytokine were normalized to
pg/l00Jlg of protein . as determined by BeA protein assay. To investigate the
systemic levels of Th 1, Th17 . and Th2 cytokines in humans, peripheral blood was
obtained from normal patients and patients with either premalignant lesions or
HNSCC . and plasma was also analyzed by cytokine bead array for presence of IFN-y,
IL-2, IL-17 A, IL-4, and IL-I0 (Fig 3.8b). While no difference was detected between
plasma levels of IFN-y and IL-2 for all three groups . premalignant lesion tissue was
found to contain a great deal more of both of these Thl cytokines compared to both
normal/adjacent and HNSCC tissue (Fig 3.8a). Unexpectedly, HNSCC tissue was
found to have a significant increase in IFN-y compared to normal/adjacent tissue
(Fig 3.8a). Analysis of IL-17 A revealed a significant decrease in this cytokine in the
plasma of HNSCC patients compared to controls and a sizeable Significant increase
in this cytokine in premalignant tissue compared to both normal/adjacent and
HNSCC tissue (Fig 3.8a and b). Finally. while IL-4levels were found to be
undetectable in both plasma and tissue, analysis of the Th2 cytokine IL-I0 showed a
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trend towards an increase in the level of this cytokine in the plasma of HNSCC
patients compared to controls and a significant increase in the level of this cytokine
in the HNSCC tissue compared to normal/adjacent tissue (Fig 3.8a and b). This data
indicates that, as observed in mice, human premalignant tissue is associated with a
large increase in inflammatory Thl and Th17 cytokines. While human HNSCC tissue
is associated with the expected increase in the immunosuppressive cytokine IL-I0,
it is also unexpectedly associated with an increase in the Th 1 cytokine IFN-y
compared to normal/adjacent controls.
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Fig 3.8 Levels of IFN-y, IL-2, and IL-17 A are increased in human premalignant
tissue compared to normal/adjacent human tissue and human UNsee tissue,
while levels of IFN-y and IL-i0 in UNSee tissue are increased compared to
normal/adjacent controls.
Cytometric bead array analysis of human normal/adjacent, premalignant, and
HNSCC tissue lysate, with normalization to 100 Jlg of protein (as determined by BCA
protein assay), with at least 6 samples per group (a), and cytometric bead array
analysis of plasma from normal, premalignant lesion-bearing, and HNSCC-bearing
patients, with at least 23 samples per group (b). *, p < O.OS. ***, P < 0.001.
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3.4 Discussion
Depending on a multitude of factors, the immune system is capable of either
mounting a beneficial response against dysplastic cells or promoting tumor
development and progression. As each individual component of an immune
response is not always consistently beneficial or detrimental, it is essential to
investigate the changes in immune phenotype during different mechanisms of
tumor initiation and development for different types of malignancies. This study
examined the alterations in various immune populations during carcinogen-induced
development of premalignant oral lesions and HNSCC. The development of oral
premalignant lesions is shown to be associated with an increase in percentage of
conventional lymphocytes expressing activation and memory markers in cervical
lymph nodes of 4NQO-treated mice compared to both control and HNSCC-bearing
mice, changes that are not accompanied by a significant increase in regulatory T
cells. Specifically, no significant difference was detected between percentages of
Teonv cells positive for the early activation marker CD69, a glycoprotein expressed
within an hour after stimulation which rapidly declines after 4-6 hours, while levels
ofTconv cells positive for CD25, a marker induced within 2-24 hours of stimulation
which persists for a few days after stimulus withdrawal, and Tconv cells with
upregulated CD44, an adhesion molecule upregulated on T cells after activation with
antigen and maintained until memory cell death, were both increased in lymph
nodes from premalignant lesion-bearing mice compared to control mice and
HNSCC-bearing mice (201, 206, 207). This data indicates that, at the time when
lesions become detectable, an immune response has been mounted in the dysplastic
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tissue and has been present for some time. In addition, lymph node cells from
premalignant lesion-bearing mice have a minor, yet significant, increase in Tconv
cells bearing the exhaustion marker KLRG1, a receptor upregulated by T cells upon
repetitive antigenic stimulation which induces T cell proliferative dysfunction, and a
trend towards an increase in Tconv cells bearing the exhaustion marker PD-l, an
inhibitory receptor upregulated during chronic T cell stimulation which induces T
cell unresponsiveness, compared to both control and HNSCC-bearing mice (202,
208-211). Also, while the premalignant stage is not associated with a significant
decrease in conventional T cells or a significant increase in regulatory T cells, the
ratio of CD4+ conventional to regulatory T cells is decreased compared to control to
an extent that matches the CD4+ conventional to regulatory T cell ratio of HNSCCbearing mice. In addition, the proliferative capacity of CD4+ conventional T cells and
the suppressive capacity of the CD4+ regulatory T cells appears to progressively
decrease throughout the development of HNSCC. This data indicates that, by the
time lesions become detectable, the immune reaction might already be starting the
transition toward the immune environment seen in the setting of HNSCC.
The classical view of immunoediting typically identifies a beneficial
antitumor response as involving an increase in IFN-y secreting Thl and Tcl cells
with a concurrent decrease in Th2 cells (203). A shift in the opposite direction is
often seen in peripheral blood and tumor-infiltrating cells of cancer patients. The
current study reveals that both mice with oral premalignant lesions and,
unexpectedly, mice with HNSCC exhibit an increased Thl and Tcl response without
any concomitant change in Th2 response compared to control. Likewise, human
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premalignant tissue and HNSCC tissue was found to have an increase in IFN-y levels
compared to normal/adjacent controls. This data contradicts earlier human studies
showing a local and systemic skewing from a Thl response to a Th2 response in
patients with HNSCC (28, 176). This brings up two major questions: #1) is the Thl
and Tcl response that is so elevated in the setting of HNSCC actually promoting
tumor growth, and #2) is the Thl and Tcl response at the premalignant stage
performing the same role as the Thl and Tcl response observed at the HNSCC
stage? Interferon-y expression has previously been shown to be associated with
tumor promotion (120, 121, 212 . 213) . notably in carcinogen-induced tumors of
epithelial origin (212) and involving upregulated Th17 expression (121). In
addition, the timing of the Th1 and Tcl response may discern between different
purposes of the response. It is interesting to note that the IFN -y related response at
the premalignant stage is characterized by an increase in Tcl cells to a greater
extent than the increase in Thl cells, while the IFN-y response at the HNSCC stage
shifts to a Th 1-dominated reaction. Perhaps the source of the IFN -y is significant in
defining its role in the anti- or pro-tumor immune response. Further investigation
into the specific roles of Th1 cells, Tcl cells, and IFN -y during tumor development
and progression will help elucidate its role in the tumor microenvironment in
4NQO-induced HNSCC carcinogenesis.
The role of the Th 17 population remains somewhat ambiguous; some studies
have indicated that these cells can work with Th1 cells to help eliminate
malignancies while other studies have identified Th17 cells as tumor-promoting,
often citing their pro-angiogenic effects (204, 205). This study revealed that the
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Th17 response increases in mice and humans bearing premalignant lesions
compared to controls, and then falls in mice and humans bearing HNSCC. This could
indicate that the Th 17 response seen during early development of HNSCC
represents an anti-tumor response. As Tregs and Th17 cells have been shown to
have an inversely proportional relationship (214), the decrease in Th17 cells seen in
HNSCC-bearing mice may be related to the simultaneous increase in the Treg
popUlation. It will be important to determine the relationship between these two
populations during the progression to HNSCC with future experimentation. In
addition, mice bearing premalignant lesions were found to have an increase in a
CD4-, IL-17 A-expressing population of cells that does not appear to be Tc17 cells
(Fig 3.6a). Determining the identity of this cell population through costaining for IL17A and other cells known to occasionally express IL-17 A, such as yo T cells or mast
cells (215, 216), will be important for future investigation into the functional
implications of IL-17 A-producing populations during HNSCC carcingogenesis.
We have evaluated the multitude of immune reactions in 4NQO-treated mice
during the development of HNSCC, and we have begun to evaluate these same
reactions in humans during the development of HNSCC. At this point, it is essential
to investigate the functional impact of the individual cell populations that are
upregulated at the premalignant stage or after HNSCC establishment. This can be
accomplished through analysis of tumor progression in 4NQO-treated mice with
depleted CD4 . CD8 . or CD4 and CD8 cells. Investigation into the role of IFN -y in the
progression of HNSCC can be carried out in mice with depleted or neutralized IFN-y.
Future studies will help to elucidate the links between these cell subsets and tumor
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development. Investigation into whether the responses described in this study are
beneficial in any way, and if they can be further manipulated to combat tumor
progression, is highly important to developing new treatment strategies for HNSCC.
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CHAPTER 4: DENDRITIC CELL VACCINATION OF PREMALIGNANT
LESION-BEARING MICE

Aim 2: To use premalignant lesion-pulsed dendritic cells in vivo to skew the

immune phenotype within mice bearing premalignant lesions towards
immunity against further development a/premalignant oral lesions and
progression to HNSCC.

4.1 Introduction
Head and neck squamous cell carcinoma (HNSCC) is an aggressive
malignancy that has had a 5-year survival rate of around 50% for over 30 years
(173 217). Developing from oral keratinizing epithelial cells in a progressive
J

fashion, both premalignant oral lesions and HNSCC have a high incidence of
recurrence. This malignancy has also been consistently associated with extensive
immune manipulation, including upregulation of both immunosuppressive
regulatory T cells and inflammatory cell types (163 164, 176, 177, 218, 219). The
J

high incidence of recurrence and systemic immune manipulation are large
contributors to the low survival rate of HNSCC (173, 186, 217).
Dendritic cell vaccination involves the exposure of dendritic cells to tumorassociated antigens (TAAs) through one of a variety of mechanisms. Primed
dendritic cells are then matured and injected into the recipient with the intention of
stimulating the recipient's own T cells to specifically target tumor tissue (220). In
the case of HNSCC, however, the patient's immune system at the point of initiation of
immunotherapy may have been compromised to the point that it is not capable of
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mounting a sufficient immune response to vaccination. While established HNSCC
has been shown to be associated with extensive immune manipulation, during the
premalignant stages of progression, levels of activated T cells with a memory
phenotype, including inflammatory Thl, Tcl and Th17 cells increase (218). As such,
this time may be optimal for initiation of immunotherapeutic techniques, since the
immune system is already stimulated.
The utilization of this technique during the premalignant stage of HNSCC
depends on the presence of common antigens that are upregulated at both the
premalignant and malignant stages compared to normal tissue. Our lab identified
several common TAAs, including EGFR, RAGE, and MUC1, in mice with 4NQO
carcinogen-induced premalignant oral lesions and HNSCC, as well as in patients
(136,180). Previous work also revealed that in vitro sensitization of human PBML
with autologous premalignant lesion lysate resulted in increased IFN-y release from
sensitized PBML upon subsequent challenge with autologous premalignant lesion or
HNSCC lysate and increased cytolytic activity of sensitized PBML against challenge
with premalignant lesion or HNSCC cells (136). Additional in vitro work showed
that sensitization of mouse splenocytes with premalignant lesion lysate-pUlsed
dendritic cells resulted in increased IFN-y release from sensitized splenocytes upon
subsequent challenge with premalignant lesion or HNSCC lysate (180). This
provides the rationale for the use of premalignant tissue as the source of antigen to
stimulate a protective immune response against the further development of
premalignant lesions and HNSCC.
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In the current study, mice treated with 4NQO until the development of
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premalignant oral lesions were vaccinated with dendritic cells pulsed with either
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premalignant lesion lysate or normal tongue epithelium lysate. Lysate was used as
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an antigenic source to provide an increased amount of potentially immunogenic
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antigens that the dendritic cells could present, rather than limiting presentation to
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one specific antigen. As mUltiple rounds of splenocyte sensitizations was required
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for activation in previous in vitro studies (180), three separate vaccinations were
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administered: the first was given at the onset of premalignant lesions, the second
was given 1 week after the first, and the final booster was given 7 weeks after the
first (Fig 4.1). To determine immune response in vaccinated mice over time, mice
were sacrificed at two timepoints: an early timepoint at 4 weeks after the first
vaccination and a late timepoint at 8 weeks after the first vaccination (1 week after
the final booster) (Fig 4.1). Lesion progression as well as immune response to
vaccination was monitored. Somewhat surprisingly, both mice treated with the
premalignant lesion-pulsed dendritic cell vaccine (DCpm) and, to a lesser extent,

2 Month old C5781/6 Mouse
Identified premalignant oral lesions

BM-derived mDCs

II

-~~;:;~s~'fg~"-~I"-s~~ __

.

.

Identified oral HNSCC

------.j ~~~~~~~~i~;:
~

Cease 4NQO
treatment upon
PM lesion
development

Sack at 4
weeks

Sack at 8
weeks

Fig 4.1 Representation of vaccination schedule.
mice treated with the normal tongue epithelium lysate-pulsed dendritic cells (DCnt)
had an improved clinical course compared to 4NQO-treated controls. DCnt mice had
an early increase in cervical lymph node cellularity and levels of multiple immune
effectors, while DCpm treated mice had a delayed increase in these same effectors.
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4.2 Materials and Methods

Oral HNSCC carcinogenesis
Five mg/ml 4NQO was administered in the drinking water (diluted to 50
j.lg/ml) of 2 month old (at start) female C57BL/6 mice (Charles Rivers Laboratory,
Wilmington, MA)) until development of premalignant oral lesions (6-8 weeks) or
HNSCC (12-16 weeks). Control mice received propylene glycol diluent control. To
monitor development of premalignant oral lesions and HNSCC, oral cavities of
4NQO-treated mice were endoscoped weekly using a Stryker 1.9mm x 30° scope and
a Stryker 1088 HD camera. Mice were sedated with inhaled isoflurane (Pi ramal
Healthcare, Mumbai, India) during the procedure.

Dendritic cell generation.. pulsing.. and maturation
Cells were collected from C57BI/6 mouse femoral bone marrow and cultured
for 5-6 days with 1000 U/ml GM-CSF (R&D Systems, Minneapolis, MN) to stimulate
the development of dendritic cells. Dendritic cells were pulsed by 12 hours of
incubation with 25 f..lg/mllysate of premalignant lesion-bearing tissue from 4NQOtreated mice or normal tongue epithelial tissue from control mice. Tongue
epithelium was obtained after incubation of tongue fragments with Dispase II
(Roche, Florence, SC) and lysed through sonication, after which protein
concentration was determined by BCA protein assay (Pierce, Rockford, IL) per
manufacturer's instructions. Dendritic cells were then matured by 48 hrs of culture
with 10 ng/ml GM-CSF and 0.1
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Vaccine regimen
Vaccination was by injection of lxl0 6 bone marrow-derived premalignant
lesion lysate- or normal tongue epithelium lysate-pulsed dendritic cells in SO J..lI
serum-free medium into the ventral tongue of 4NQO-treated mice under inhaled
isoflurane sedation (Piramal Healthcare, Mumbai, India). 4NQO-treated controls
were injected with SO III of saline into the ventral tongue of 4NQO-treated mice. The
first vaccination was given to mice once all 4NQO-treated mice were determined
through oral cavity endoscopy to exhibit premalignant oral lesions. A second
vaccination was administered 7 days after the first. Some mouse groups were
sacrificed four weeks following the first vaccination. A third vaccination was
administered 7 weeks after the first vaccination for the remaining mice, and these
mice were sacrificed 7 days later. Tongues were harvested, sectioned, and stained
with hematoxylin and eosin for histologic analysis.

Cervical lymph node processing
Cervical lymph nodes were harvested from mice and homogenized via a
Stomacher 80 homogenizer (Seward, West Sussex, UK) set on high for 90 sec. Cells
were passed through a 40-J..lm cell strainer (BD Falcon, San Jose, CA) and rinsed with
Hank's Buffered Saline Solution (HBSS, Invitrogen, Carlsbad, CA) to remove debris.
Cell number was determined by counting cells excluding trypan blue using a
hemocytometer.
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Flow cytometric analysis ofsurface markers and Foxp3 expression
All reagents in this section were from BD Bioscience (San Jose, CA) unless
otherwise stated. In order to detect levels of CD8 and CD4 positive cells in relation
to Foxp3, ex vivo cervical lymph node cells in single-cell suspension were washed
once in Stain Buffer and resuspended at lxl0 7 cells/ml. In order to detect
expression ofMHCII (I-Ab for C57/b16 mice), CD80, and CD86 on CDllc positive
dendritic cells, cultured matured dendritic cells in single-cell suspension were
washed once in Stain Buffer and resuspended at lxl0 7 cells/ml. Nonspecific
staining oftotallxl0 6 cells was blocked with FBS and anti-CD16/32 monoclonal
antibody prior to cell surface staining with the following antibodies: PerCP-Cy5.5
CD4, FITC CDBa, FITC CDllc, PE C025, PE I-Ab, APC CD69, APC CD80, and PE-Cy7
CD86. Intracellular staining for PE-Cy7 Foxp3 was performed after fixation with
Foxp3 Fixation Buffer and permeabilization with Foxp3 Permeabilization Buffer.
Extent and frequency of positively stained cells was visualized using flow cytometry
(FACSCanto, San Jose, CA).

Flow cytometric analysis ofcytokine expression
All reagents in this section were from BD Bioscience (San Jose, CA) unless
otherwise stated. In order to detect intracell ular cytokines, single-cell suspensions
of cervical lymph node cells were restimulated for 4 hours at 37°C with 50 ng/ml
phorbol 12-myristate 12-acetate (PMA), 1 Jlg/ml ionomycin, and brefelden A
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solution.

Nonspecific staining of total of lxl0 6 cells was blocked with FBS and anti-

CD16/32 monoclonal antibody prior to cell surface staining with the following
antibodies: PerCP-CyS.S CD4 and PE-Cy7 CD8a. Intracellular staining for PE IL-17 A,
FITC IFN-y, APC IL-4, APC IL-I0 and Alexa Fluor 488 IL-13 (eBioscience} San Diego,
CA) was performed after fixation/permeabilization with Cytofix/Cytoperm. Extent

and frequency of positively stained cells was visualized using flow cytometry
(FACSCanto, San Jose} CA).

Cytokine bead array
All reagents in this section were from BD Bioscience (San Jose, CA) unless
otherwise stated. In order to detect cytokines released into supernatant, single-cell
suspensions of cervical lymph node cells or dendritic cells were restimulated for 4
hours at 37°C with 50 ng/ml PMA and 1 I-lg/ml ionomycin without addition of
brefeldin A or cervical lymph node cells were activated for 3 days in the presence of
anti-CD3/anti-CD28 beads. To determine degree of cytokine release in response to
challenge, some lymph node cells were incubated for three days with 25fl.g/ml of
normal tongue epithelium lysate, premalignant epithelium lysate or HNSCC
epithelium lysate in the presence of anti-CD3/anti-CD28 beads. Presence/level of
IFN-y, IL-17 A, IL-4, IL-IO} and IL-13 in lymph node cell supernatant and IL-12, IL-6,
TNF, IL-I0, IL-la and IL-lf3 in dendritic cell supernatant was determined using a
mouse cytometric bead array Thl/Th2/Th17 cytokine kit and cytometric bead
array flex sets for individual cytokines according to the manufacturer's instructions.
Relative amount of each cytokine was analyzed using FCAP Array software.
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Statistical analysis
Data were reported using the mean as a measure of central tendency ±
standard error of the mean. To compare one variable condition between groups, the
2-tailed Student's t-test was used. To evaluate significant differences between lesion
numbers for each mouse group, the Mann-Whitney U Test was used. To evaluate if
any significant differences exist between histologic scores, a chi squared test was
used. Significance was reported in the 95% confidence interval.
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4.3 Results

DCpm vaccination and, to a lesser extent, Dent vaccination result in an improved
clinical response compared to 4NQO-treated controls.
The ultimate goal of any interventional immunotherapeutic approach is an
improvement in clinical status. To monitor development of lesions in 4NQO-treated
mice, oral cavities were examined through weekly endoscopy and number of visible
lesions was counted. Analysis of lesion number revealed that DCpm vaccination
resulted in a significant decrease in the number of lesions compared to 4NQO
control at 6, 7, and 8 weeks (Fig 4.2a). DCnt vaccination resulted in a significant
decrease in number of lesions compared to 4NQO control at 8 weeks only (Fig 4.2a).
Mice were sacrificed at 4 and 8 weeks post-vaccination and tongues were
harvested, processed, and random paraffin-embedded sections were analyzed for
histologic score (normal, mild dysplasia, moderate-severe dysplasia, invasive
carcinoma). Histologic analysis revealed a trend towards an increase in the overall
degree of dysplasia at 4 weeks in mice administered the Dent vaccine compared to
4NQO-treated controls. Similar to the results from gross analysis, histologic analysis
also revealed a trend towards a decrease in the overall degree of dysplasia at 8
weeks in mice administered either the DCnt or DCpm vaccine compared to 4NQOtreated controls (Fig 4.2b). This indicates that DCpm vaccination may decrease the
clinical lesion burden in mice treated with 4NQO, and, surprisingly, DCnt
vaccination also appears to decrease clinical lesion burden, though at a later
timepoint.
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Fig 4.2 DCpm vaccination and DCnt vaccination result in an improved clinical
response compared to 4NQO-treated controls.
Number of visible lesions (a) as determined by weekly endoscopy of oral cavities of
4NQO-treated mice administered dendritic cells pulsed with normal tongue
epithelium lysate (DCnt), dendritic cells pulsed with premalignant lesion lysate
(DCpm), or saline (4NQO Ctl) with at least 15 mice per groups. Data represent
mean ± SEM. *, P < 0.05. **, p < 0.01. ***, P < 0.001 (Mann-Whitney U test) . At 4
weeks and 8 weeks post-first vaccination, 4NQO Ctl, DCnt and DCpm mice were
sacrificed and tongues were harvested, sectioned, and random sections were
stained with hematoxylin and eosin for histopathologic analysis (b) with tongues
from at least 11 mice per group. Data represent percentage, and statistical
sie:nificance was determined bv chi sauared test.

DCnt vaccination results in an early increase in lymph node cell count, while DCpm
vaccination results in a delayed increase in lymph node cell count.

The development of malignancies is often associated with hyperplasia of
draining lymph nodes, whether due to reactive hyperplasia, metastasis, or both
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(195). To determine the degree of lymph node hyperplasia among the various
mouse groups, cervical lymph nodes from control mice, 4NQO-treated control mice,
4NQO-treated Dent mice, and 4NQO-treated DCpm mice were harvested at 4 and 8
weeks post-first vaccination, and the number of try pan blue-excluding cells were
counted. At 4 weeks post-first vaccination, DCnt vaccinated mouse lymph nodes
contained significantly more cells than all other groups (Fig 4.3a). At 8 weeks postfirst vaccination, however, DCpm and DCnt vaccinated mouse lymph nodes
contained greater numbers of cells compared to control and 4NQO control mouse
lymph nodes (Fig 4.3b). Also at 8 weeks . 4NQO control mouse cervical lymph nodes
contained significantly more cells than control mice (Fig 4.3b). This indicates that
there is a more rapid response in lymph node cell proliferation after Dent
vaccination compared to DCpm vaccination. However, the proliferative response to
the DCpm vaccine occurs to a great extent by the later timepoint.

Dent vaccination results in an early increase in levels of Tconv cells and CD4 Tregs

J

while both DCnt and DCpm vaccination result in a decreased percentage ofCD4 Tconv
cells and increased absolute number of CDB Tconv cells and Tregs at 8 weeks
compared to 4NQO-treated controls.
Many solid carcinomas have been shown to be associated with local and
systemic immunosuppression (163, 164. 176). This includes downregulation of
stimulatory immune cells, such as CD4+ and CD8+ conventional T cells, and
upregulation of suppressive immune cells. One suppressive cell population that is
often upregulated as a part of this phenomenon is the regulatory T cell population,

Chapter 4

75

DC Vaccination of Premalignant Lesion-Bearing Mice

Premalignant Oral Lesion Immunobiology: Immune Modulation and Vaccination

**

a. 2.5E+07

b.2.5E+07

o Control

o Control

El4NQO Ctl

2.0E+07

IIIIOCnt

**

,------,

1.5E+07

El4NQO Ctl

2.0E+07

III!IIOCnt

-OCpm

-OCpm

1.5E+07

1.0E+07

1.0E+07

5.0E+06

5.0E+06

O.OE+OO

O.OE+OO

4 Week CLN Cell count

8 Week CLN Cell count

Fig 4.3. DCnt vaccination results in an early increase in lymph node
cellularity, while DCpm vaccination results in a delayed increase in lymph
node cellularity.
At 4 weeks and 8 weeks post-first vaccination} control mice} 4NQO-treated control
mice (4NQO Ctl)} DCnt-vaccinated mice (DCnt) and DCpm-vaccinated mice (DCpm)
were sacrificed and cervical lymph nodes were harvested and processed to singlecell suspensions} and trypan-blue excluding cells were counted with at least 5 mice
per group. Data represent mean ± SEM of cell number at 4 weeks post-first
vaccination (a) and 8 weeks post-first vaccination (b). *} p < 0.05. **} p < 0.01. ***} P
< 0.001 (2-tailed Studenfs t-test).
identified by expression of the transcription factor Foxp3 (163} 164} 176). Our lab
had previously shown that locoregional regulatory and conventional T cell numbers
are both increased in mice with HNSCC (218). To determine the relative
composition of conventional and regulatory T cells in 4NQO-treated mice
administered DC vaccination} lymph node cells collected at 4 and 8 weeks post-first
vaccination were stained for surface expression of CD4 and CD8 and intracellular
expression of Foxp3. Proportions of cells expressing each marker were determined
through flow cytometric analysis} and numbers of cells expressing each markers
were determined by multiplying the percent positive by the number of lymph node
cells for each individual mouse. At 4 weeks post-first vaccination} a1l4NQO-treated
mouse groups had a decreased percentage of Foxp3- CD4+ Tconv cells and an
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increased percentage of CD4+ Treg cells compared to controls (Fig 4.4a and b). At
this timepoint, DCnt mice exhibited an increase in percentage and absolute number
of Tconv cells and an increase in absolute number of CD4 Tregs compared to 4NQOtreated controls (Fig 4.4c). At 8 weeks post-first vaccination, both DCnt and DCpm
mice exhibited a decrease in percentage of CD4+ Teonv cells compared to 4NQO
controls (Fig 4.4a and b). Analysis of cell numbers revealed an increase in the
absolute number of CD8 Tconv cells and Treg cells in both DCnt and DCpm mouse
lymph nodes compared to 4NQO controls (Fig 4.4c). This data indicates that DCnt
vaccination may work early on to stimulate an increase in Tconv and Treg cells.
While DCpm mice show no differences from 4NQO controls early on . DCpm
vaccination appeared to affect a delayed increase in Tconv and Treg cells at 8 weeks
after the initial vaccination.

Dent vaccinated mice exhibit a decrease in percentage but increase in absolute
number of activated CD4 Tconv cells 4 weeks, while both Dent and DCpm vaccinated
mice exhibit an increase in absolute number of activated CDB Tconv cells at B weeks
compared to 4NQO-treated controls.
An optimal immune response to antigenic stimulation involves the activation
of conventional T cells (198). To determine the proportions of conventional T cells
bearing markers for activation, CD4+Foxp3- and CD8+Foxp3- T lymph node cells
were analyzed for expression of CD25 and CD44. While often used as a marker for
regulatory T cells, CD25 expression on foxp3- conventional T cells is expressed
within 2-24 hours after stimulation and persists for a few days after withdrawal of
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Fig 4.4 DCnt vaccination results in an increase in levels of Tconv cells and CD4
Tregs at 4 weeks, while both DCnt and DCpm vaccination result in a decreased
percentage of CD4 Tconv cells and increased absolute number of CDB Tconv
cells and Tregs at B weeks compared to 4NQO-treated controls.
Representative results (a) and graphical representation (b) of flow cytometric
staining of cervical lymph node cells from control, 4NQO-treated control (4NQO Ctl),
DCnt-vaccinated (DCnt) and DCpm-vaccinated (DCpm) mice at 4 and 8 weeks postfirst vaccination with at least 5 mice per group. Data represent mean ± SEM. *, P <
0.05. **, p < 0.01 (2-tailed Student's t-test). Total numbers of populations (c) were
determined by multiplying the percent positive by the number of cervical lymph
node cells for each individual mouse. Data represent mean ± SEM. *, P < 0.05. **, p
< 0.01. ***, P < 0.001 (2-tailed Student's t-test).

the stimulus. CD44 is a glycoprotein involved in cell adhesion and migration, and its
increased expression is indicative ofT cell antigen experience (200, 201).
Percentages of cells bearing CD25 and CD44 were determined by flow cytometric
analysis, and total numbers of cells bearing these markers were determined by
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multiplying percent positive by the number of lymph node cells for each individual
mouse. At 4 weeks post-first vaccination, percentages of CD25+ and CD44 hi CD4 and
CD8 Tconv cells are decreased in Dent mouse lymph nodes compared to 4NQO
controls (Fig 4.5a and b). After factoring in cell numbers, DCnt vaccinated mouse
lymph nodes were found to have an increased absolute number of CD25+ and CD44 hi
CD4 Tconv cells compared to 4NQO controls (Fig 4.5c). At this timepoint, the only
significant difference between the DCpm and 4NQO control group is a decrease in
percentage of CD44 hi COB Tconv cells in DCpm-vaccinated mice (Fig 4.5a and b).
This could possibly be due to antigen-specific cells dying upon TCR restimulation in

vivo. At 8 weeks post-first vaccination, both vaccinated groups see a significant
increase in number of CD2S+ and CD44 hi CD8 Tconv cells compared to 4NQO
controls, and DCpm-vaccinated mice also exhibit an increase in CD44 hi CD4 Tconv
cells compared to 4NQO controls (Fig 4.5c). This data indicates that both DCnt and
DCpm vaccination tend to result in an increase in activated T cells compared to
4NQO treatment alone by 8 weeks post-first vaccination.

DCnt vaccination results in an early increase in Thl and Tel levels while both DCnt
l

and DCpm vaccination result in an increase in Tel levels at 8 weeks compared to
4NQO-treated controls.
T cells can be further subdivided based on their expression of certain
cytokines that dictate differing effector functions. Thl cells (and a smaller subset of
CD8+ cells known as Tcl cells) secrete IFN-y and are generally considered as
inflammatory. They are traditionally thought of as beneficial for anti-tumor
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Fig 4.5 DCnt vaccinated mice exhibit a decrease in percentage but increase in
absolute number of activated CD4 Tconv cells 4 weeks, while both DCnt and
DCpm vaccinated mice exhibit an increase in absolute number of activated
CD8 Tconv cells at 8 weeks compared to 4NQO-treated controls.
Representative results (a) and graphical representation (b) of flow cytometric
staining of cervical lymph node cells from control, 4NQO-treated control (4NQO Ctl),
DCnt-vaccinated (DCnt) and DCpm-vaccinated (DCpm) mice at 4 and 8 weeks postfirst vaccination with at least 5 mice per group. Data represent mean ± SEM. *, P <
0.05. **, p < 0.01. ***, P < 0.001 (2-tailed Student's t-test). Total numbers of
populations (c) were determined by multiplying the percent positive by the number
of cervical lymph node cells for each individual mouse. Data represent mean ± SEM.
*, P < 0.05. **, p < 0.01. ***, P < 0.001 (2-tailed Student's t-test).
immunity (203). However, recent research in our laboratory has shown that Thl
and Tcl cells are upregulated in both the premalignant and malignant stages of
HNSCC (218). To evaluate the populations ofThl and Tcl cells in draining lymph
nodes of control, 4NQO control, DCnt, and DCpm mice, lymph node cells were
stained for surface expression of CD4 and CDB and intracellular expression of the
Thl and Tcl cytokine IFN-y after 4 hours incubation with PMA, Ionomycin and
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brefeldin A.. In addition, supernatants of lymph node cells incubated for 4 hours in
PMA and Ionomycin were analyzed by cytometric bead array for levels of IFN-y. At
4 weeks post-first vaccination, lymph nodes from DCnt vaccinated mice contain a
greater percentage and number ofThl cells and a greater absolute number ofTcl
cells compared to all other groups (Fig 4.6a, b, c). This is supported by CBA data
showing an increase in IFN-y released into the supernatant of Dent mouse lymph
node cells compared to all other groups (Fig 4.6d).
At 8 weeks post-first vaccination, DCnt mouse lymph nodes have a decreased
percentage ofThl cells and an increased percentage ofTcl cells compared to 4NQO
controls (Fig 4.6a and b). After factoring in cell number, both DCnt and DCpm
mouse lymph nodes were found to contain a greater absolute number ofTcl cells
compared to 4NQO controls (Fig 4.6c). Analysis of cytokines secreted in response to
4 hour stimulation with PMA and Ionomycin revealed no significant changes in the
levels of IFN-y in the supernatant of ex vivo lymph node cells from vaccinated mice
compared to 4NQO controls (Fig 4.6d). To determine cytokine release in response
to more extended stimulation, lymph node cells from 8 week post-first vaccination
mice were cultured for 3 days in the presence of anti-CD3/anti-CD28. After the
three day stimulation, cytometric bead array was used to measure levels of IFN-y in
the supernatant. Cytokine analysis revealed a huge increase in IFN-y levels in the
supernatant of DCpm and Dent mouse lymph node cells compared to control and
4NQO control (Fig 4.6e). This data indicates that Dent vaccination induces an early
increase in Thl and Tcl cells, but by the later timepoint, both DCnt and DCpm
vaccination induce a Tcl-type reaction.
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Fig 4.6 DCnt vaccination results in an increase in Thl and Tcllevels at 4
weeks, while both DCnt and DCpm vaccination result in an increase in Tcl
levels at 8 weeks compared to 4NQO-treated controls.
Representative results (a) and graphical representation (b) of flow cytometric
staining of cervical lymph node cells from control, 4NQO-treated control (4NQO Ctl),
DCnt-vaccinated (DCnt) and DCpm-vaccinated (DCpm) mice at 4 and 8 weeks postfirst vaccination with at least 5 mice per group. Data represent mean ± SEM. *, P <
0.05. **, p < 0.01. ***, P < 0.001 (2-tailed Student's t-test). Total numbers of
populations (c) were determined by multiplying the percent positive by the number
of cervical lymph node cells for each individual mouse. Data represent mean ± SEM.
*, P < 0.05. **, p < 0.01. ***, P < 0.001 (2-tailed Student's t-test). Cytometric bead
array analysis (d) of supernatant of 4 week and 8 week control, 4NQO Ctl, DCnt, and
DCpm mouse cervical lymph node cells after stimulation for four hours with PMA
and ionomycin, with at least 5 mice per group. Data represent mean ± SEM. *, P <
0.05. **, p < 0.01. ***, P < 0.001 (2-tailed Student's t-test). Cytometric bead array
analysis (e) of supernatant of 8 week control, 4NQO CtI, DCnt, and DCpm mouse
cervical lymph node cells after 3 day stimulation with anti-CD3/anti-CD28 beads
with at least 4 mice per group. Data represent mean ± SEM. *, P < 0.05 (2-tailed
Student's t-test).
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Dent vaccination results in an early increase in absolute number ofTh17 and Tc17
cells, while both DCnt and DCpm vaccination result in an increase in absolute number
ofTh17 and Tc17 cells at 8 weeks compared to 4NQO-treated controls.
Th17 cells (and a smaller subset of CD8+ cells known as Tcl7 cells) secrete
IL-17 A, among other cytokines, and induce a greater degree of inflammation
compared to Thl cells. Their role in antitumor immunity is less clear. They are
highly proinflammatory and proangiogenic, qualities that generally promote
tumorigenesis. They are also upregulated in many different tumor types; however,
in some tumor types, like lung cancer and ovarian cancer. an increased presence of
IL-17 A and Th17 cells is actually associated with improved prognosis (123, 125,
204,205). Recent data from our lab showed that Th17 cells are highly upregulated
in mice bearing premalignant oral lesions, only to decrease in the draining lymph
nodes of HNSCC-bearing mice (218). To evaluate the populations ofTh17 and Tc17
cells in draining lymph nodes of control, 4NQO control, DCnt, and DCpm mice, lymph
node cells were stained for surface expression of CD4 and CDB and intracellular
expression of the Th17 and Tcl7 cytokine IL-l7a after 4 hours incubation with PMA,
Ionomycin and brefeldin A. In addition, supernatants of lymph node cells incubated
for 4 hours in PMA and Ionomycin were analyzed by cytometric bead array for
levels of IL-17 A. At 4 weeks post-first vaccination, Dent mouse lymph nodes have
an increased absolute number of Th17 and Tcl7 cells compared to 4NQO controls,
corresponding to an increased secretion of IL-17 A from Dent lymph node cells
compared to 4NQO lymph node cells in response to 4 hour stimulation (Fig 4.7c and
d).
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Fig 4.7 DCnt vaccination results in an increase in absolute number of Th17
and Tc17 cells at 4 weeks, while both DCnt and DCpm vaccination result in an
increase in absolute number of Th17 and Tc17 cells at 8 weeks compared to
4NQO-treated controls.
Representative results (a) and graphical representation (b) of flow cytometric
staining of cervical lymph node cells from control, 4NQO-treated control (4NQO Ctl),
DCnt-vaccinated (DCnt) and DCpm-vaccinated (DCpm) mice at 4 and 8 weeks postfirst vaccination with at least 5 mice per group. Data represent mean ± SEM. No
significant differences were found in percentages of CD4 +IL-17 A+ or CD8+ IL-17 A+
cells at 4 or 8 weeks (2-tailed Student's t-test). Total numbers of populations (c)
were determined by multiplying the percent positive by the number of cervical
lymph node cells for each individual mouse. Data represent mean ± SEM. *, P <
0.05. **, p < 0.01. ***, P < 0.001 (2-tailed Student's t-test). Cytometric bead array
analysis (d) of supernatant of 4 week and 8 week control, 4NQO Ctl, DCnt, and
DCpm mouse cervical lymph node cells after stimulation for four hours with PMA
and ionomycin, with at least 5 mice per group. Data represent mean ± SEM. *, P <
0.05. **, p < 0.01. ***, P < 0.001 (2-tailed Student's t-test). Cytometric bead array
analysis (e) of supernatant of 8 week control, 4NQO Ctl, DCnt, and DCpm mouse
cervical lymph node cells after 3 day stimulation with anti-CD3/anti-CD28 beads
with at least 4 mice per group. Data represent mean ± SEM. *, P < 0.05 (2-tailed
Student's t-test1.
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At 8 weeks post-first vaccination, both DCnt and DCpm mice have an
increased absolute number ofTh17 and Tc17 cells compared to control and 4NQO
control (Fig 4.7c). While the supernatant of ex vivo lymph node cells shows no
significant change in IL-17 A levels in vaccinated mice compared to controls (Fig
4.7dl. supernatant ofDCnt and DCpm mouse lymph node cells stimulated for 3 days
with anti-CD3/anti-CD28 contained much higher levels of IL-17 A compared to
controls (Fig 4. 7 e). This indicates that vaccination with DCnt results in an increase
in Thl7 and Tcl7 cells early on, while vaccination with either DCnt or DCpm results
in an increase in the Th17 and Tc17 response at 8 weeks post-vaccination.

DCpm vaccination results in increased levels of IL-10 at 4 weeks, while both Dent and
DCpm vaccination results in increased levels of IL-13 at 8 weeks compared to 4NQOtreated controls.
Th2 cells can have inflammatory or anti-inflammatory effects, and they can
release mUltiple different cytokines, including IL-4, IL-lO, and IL-13. These cells
have been traditionally associated with a pro-tumorigenic phenotype. They are
often upregulated in cancers, antagonizing a beneficial Thl response (221-224).
However, our lab has shown that levels ofTh2 cytokines remain largely unchanged
in the draining lymph nodes of premalignant lesion-bearing and HNSCC-bearing
mice compared to controls (218). To evaluate the populations ofTh2 cells in
draining lymph nodes of controt 4NQO controt DCnt, and DCpm mice, lymph node
cells were stained for surface expression of CD4 and intracellular expression of the
Th2 cytokines IL-4, IL-lO, and IL-13 after 4 hours incubation with PMA, Ionomycin
and brefeldin A. In addition, supernatants of lymph node cells incubated for 4 hours
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in PMA and Ionomycin were analyzed by cytometric bead array for levels of IL-4, ILla, and IL-13. At 4 weeks post-first vaccination, DCpm mice have an increased

percentage of IL-I0 expressing CD4 T cells compared to all other groups (Fig 4.8a
and b). This is supported by data showing an increase in IL-I0 released into the
supernatant of ex vivo DCpm mouse lymph node cells incubated for 4 hours with
PMA and Ionomycin compared to all other groups (Fig 4.8d). Also at this timepoint,
DCnt mouse lymph nodes were found to have an increased absolute number of IL10 expressing CD4 T cells as well as an increased level of IL-l3 in supernatant of ex
vivo lymph node cells compared to 4NQO control (Fig 4.8c and d).
At 8 weeks post-first vaccination, DCpm mouse lymph nodes were found to
contain a decreased percentage of IL-lO-expressing CD4 T cells compared to 4NQO
controls and an increased number of IL-4-expressing CD4 T cells compared to 4NQO
controls (Fig 4.8a, b, c). DCnt mouse lymph nodes have an increased percentage and
both DCnt and DCpm mouse lymph nodes have an increased absolute number of ILl3-expressing CD4 T cells compared to 4NQO control (Fig 4.8c). Analysis of
supernatant of ex vivo cells stimulated for 4 hours with PMA and Ionomycin
revealed a significant increase in IL-l3 in both vaccinated groups compared to
4NQO control and control (Fig 4.8d). Analysis of supernatant of cells stimulated for
3 days with anti-CD3/anti-CD28 revealed a large increase in IL-lO, IL-l3 and IL-4 in
supernatant from DCnt and DCpm mouse lymph node cells compared to control and
4NQO control (Fig 4.8e). This data indicates that, while DCpm vaccination results in
an early increase in the immunosuppressive cytokine IL-IO, both DCnt and DCpm
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vaccination result in the delayed increase in multiple Th2 cytokines, especially IL13.
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Fig 4.8 DCpm vaccination results in increased levels of IL-10 at 4 weeks, while
both DCnt and DCpm vaccination results in increased levels of IL-13 at 8
weeks compared to 4NQO-treated controls.
Representative results (a) and graphical representation (b) of flow cytometric
staining of cervical lymph node cells from control, 4NQO-treated control (4NQO Ctl),
DCnt-vaccinated (DCnt) and DCpm-vaccinated (DCpm) mice at 4 and 8 weeks postfirst vaccination with at least 5 mice per group. Data represent mean ± SEM. *, P <
0.05. **, p < 0.01. ***, P < 0.001 (2-tailed Student's t-test). Total numbers of
populations (c) were determined by multiplying the percent positive by the number
of cervical lymph node cells for each individual mouse. Data represent mean ± SEM.
*, P < 0.05. **, p < 0.01. ***, P < 0.001 (2-tailed Student's t-test). Cytometric bead
array analysis (d) of supernatant of 4 week and 8 week control, 4NQO Ctl, DCnt, and
DCpm mouse cervical lymph node cells after stimulation for four hours with PMA
and ionomycin, with at least 5 mice per group. Data represent mean ± SEM. *, P <
0.05. **, p < 0.01. ***, P < 0.001 (2-tailed Student's t-test). Cytometric bead array
analysis (e) of supernatant of 8 week control, 4NQO Ctl, DCnt, and DCpm mouse
cervical lymph node cells after 3 day stimulation with anti-CD3janti-CD28 beads
with at least 4 mice per group. Data represent mean ± SEM. *, P < 0.05 (2-tailed
Student's t-test).
Chapter 4

87

DC Vaccination of Premalignant Lesion-Bearing Mice

Premalignant Oral Lesion Immunobiology: Immune Modulation and Vaccination

4.4 Discussion

The immune reaction to tumor development is a complicated and
multifaceted phenomenon. While the immune system is capable of recognizing and
attacking most dysplastic tissues, some dysplastic tissue is bound to avoid
elimination and, given time and the selective pressure of the immune system,
variants arise which have the capacity to escape recognition and/or manipulate the
immune system in ways which further the progression of the malignancy (225).
This is the case with HNSCC, a cancer that is known to upregulate
immunosuppressive cell populations such as Treg cells and promote smoldering
inflammation through chronic upregulation of inflammatory cell types (163, 164,
176,177,218, 219). In this study, we sought to halt the progression of HNSCC at the
premalignant stage through dendritic cell vaccination, with the rationale that
premalignant and HNSCC tissue share common T AAs and the immune system at the
premalignant stage has not yet been compromised by the advanced immunemanipulative tactics of an established tumor (136,180,218). Unexpectedly, both
DCpm vaccination and DCnt vaccination, though to a lesser extent, resulted in a
decrease in lesion burden compared to 4NQO treatment alone. Also, evaluation of
lymph node cells from DCpm vaccinated mice for response to a 3 day challenge with
premalignant or HNSCC lysate showed that a specific response was not being
generated (Fig 4.9). Analysis of the ex vivo immune response in vaccinated mice, as
summarized in Table 4.1, revealed an early increase in draining lymph node cell
number and levels of stimulatory immune effectors, including activated CD4 Tconv
cells, CDB Tconv cells, Th1, Tel, Th17, and Tc17 cells, for DCnt mice, while the
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immune response in DCpm mice at 4 weeks mirrored that of 4NQO control mice. At
the later timepoint, when both vaccinated groups appear to provide beneficial
clinical effects, both DCnt and DCpm mouse lymph nodes have a greater number of
cells, consisting ofimmunostimulatory cells such as activated CTLs, Tcl, Thl7 and
Tcl7 cells, and, to a lesser extent, immunosuppressive Tregs and Th2 cells. These
data indicate that DC vaccination, regardless of whether the DCs were pulsed with
normal tongue or premalignant antigens, provides a non-specific but substantial
immune stimulatory response and may be clinically beneficial.
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Fig 4.9 Cervical lymph node cells from vaccinated mice do not exhibit
specificity of reaction to premalignant lysate or UNSCC lysate challenge.
Cytometric bead array analysis of supernatant of 4 week control, 4NQO-treated
control (4NQO Ctl), DCnt-vaccinated (DCnt) and DCpm-vaccinated (DCpm) mouse
cervical lymph node cells after 3 day challenge with 25 Ilg/ml of normal tongue
epithelium lysate (NT), premalignant epithelium lysate (PM), or HNSCC lysate
(HNSCC) in the presence of anti-CD3/anti-CD28 beads with at least 4 mice per
group. No significant differences in IL-2 release (a), IFN-y release (b), IL-l7A
release (c), or IL-4 release (d) were found for the different challenges within each
mouse group (2-tailed Student's t-test).
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This study presents the evaluation of immune response in the draining
cervical lymph nodes of vaccinated and unvaccinated 4NQO-treated mice. This
method of evaluation was used because the immune response to tumor is likely to
be orchestrated in draining lymph nodes and because tongue epithelium was
determined to contain very low numbers of T cells. However, immune response to
treatment and to tumor development involves not only loco-regional responses, but
also a myriad of changes in cellular localization of immune populations following
activation. As such, it will be important to investigate immune populations present
in tongue epithelium and in the periphery to fully determine the response to
vaccination and tumor development.
Evaluation of dendritic cell maturation markers and cytokines revealed no
differences between the dendritic cells pulsed with premalignant lesion lysate and
the dendritic cells pulsed with normal tongue epithelium lysate (Fig 4.10).
Investigation into response to premalignant lysate or HNSCC lysate challenge
showed no indications of specificity of reaction of DCpm mouse lymph node cells or
DCnt mouse lymph node cells (Fig 4.9). However, DCnt vaccination clearly elicited a
more immediate response compared to DCpm vaccination, though this did not
correlate with a stronger clinical response compared to DCpm mice. DCpm
vaccination, on the other hand, resulted in very little in the way of an immediate
reaction. At the later timepoint, however, both Dent and DCpm vaccination resulted
in increased immune stimulation and improved clinical response. Additional
research into what delineates the different responses to these two vaccinations is
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necessary to determine why the DCpm vaccination promotes a delayed response
compared to the immediate response to the DCnt vaccine.
Part of the rationale for using premalignant lesion lysate as the source of
antigen to stimulate a specific in vivo response to premalignant and malignant tissue
involved the over-expression of multiple common TAAs in both premalignant and
HNSCC tissue (136, 180). However, as determined in the current study, pulsing DCs
with premalignant antigen did not result in the development of a specific response
of lymph node cells from vaccinated mice to premalignant or HNSCC antigens, and
both DCnt vaccination and DCpm vaccination resulted in a similar clinical response.
To evaluate if the clinical response seen with DCnt and DCpm vaccination is a result
of administering activated dendritic cells regardless of pulsing with lysate, another
control group was vaccinated with unpulsed, activated Des. Like both the Dent and
DCpm-vaccinated groups, there was no specific response of DC-vaccinated mouse
lymph node cells to either premalignant or HNSCC challenge (data not shown). Also,
while DC-vaccinated mice did have a clinically significant decrease in lesion burden,
there was no difference in lesion burden between the DC-vaccinated and DCnt- or
DCpm-vaccinated groups (data not shown). Therefore, it is likely that the clinical
benefit seen is solely due to an increase in numbers of activated Des. These
activated Des may pick up antigen after injection into the tongue, resulting in crosspresentation to cytotoxic T cells. It is also possible that in using tissue lysate as an
antigenic source, the extraneous components of the lysate prevented sufficient
stimulation of cells with the intended premalignant and HNSCC tissue-associated
T AAs. Future experimentation into vaccination of mice with specific T AA-pulsed
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Fig 4.10 Dendritic cells have the same expression of costimulatory markers
and cytokines whether pulsed with normal tongue epithelium lysate or
premalignant epithelium lysate.
Immature bone marrow-derived dendritic cells were pulsed with lysates of
premalignant epithelium (DCpm vaccine) or normal tongue epithelium (DCnt
vaccine), then matured with LPS. Phenotyping of dendritic cells by flow
cytometric staining (a) and cytometric bead array (b) of at least 4 separate
experiments reveal no significant differences between dendritic cell maturation
markers or cytokines between the two groups (2-tailed Student's t-test).
DCs may lead to the development of an immunotherapy providing a specific immune
response with improved clinical benefit.
HNSCC is an aggressive malignancy that has a complicated relationship with
the immune system. The development of immunotherapeutic strategies to combat
this cancer is highly important to increasing the poor survival rate of patients with
HNSCC. While the dendritic cell vaccination described in this study reduced lesion
burden by only a small amount, the immune system interactions described help to
advance our understanding of the functions of various immune cell subtypes during
the development of HNSCC. Further investigation into the intricacies of the tumorimmune system relationship will allow for more efficient development of
treatments that have a better chance of being effective in the future.
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Table 4.1 Summary of significant differences in absolute numbers of cell
populations between the 4NQO control group and the DCnt and DCpmvaccinated groups.
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CHAPTER 5: GENERAL DISCUSSION
5.1 Implications of Immune Response During HNSee Development
In the theory of immunoediting, there are three stages of immune response
during tumor development: elimination. equilibrium, and escape. Elimination
involves an anti-tumor response in which Thl and Tcl cells direct immune
effectors, including CTLs and macrophages, to clear dysplastic tissue (1, 2).
Equilibrium involves the co-evolution of tumor variants with the immune system,
often resulting in the emergence of non-immunogenic tumor variants that have
gained the ability to subvert the immune system through several mechanisms, a
stage referred to as escape (2, 17-19). However, the immune system can also
contribute to tumor development through the effects of unresolved chronic
inflammation (105-111). The mediators that promote tumor growth often overlap

with the mediators that combat tumor growth} complicating the classification of
1I

certain immune responses as anti-tuIDor" or ((pro-tumor. Careful investigation
U

into the intricacies of immune responses to the development of specific cancers is
essential to determining the true roles of the immune cells in these cancers.
HNSCC is a cancer that has been shown to have a complicated relationship
with the immune system. As such, this study aimed to further elucidate the
implications of the immune alterations observed in HNSCC by examining the
immune responses during HNSCC development. HNSCC is somewhat unique in that,
with vigilant surveillance, it may be identified in its premalignant stages as

leukoplakia or erythroplakia of the oral mucosa (173). Analysis of these
premalignant lesions in humans and mice revealed an increase in inflammatory
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cytokine levels, such as IFN-y, compared to control tissue. Analysis of the draining
cervical lymph nodes in premalignant lesion-bearing mice also revealed an increase
in stimulatory immune effectors from Tconv cells bearing markers of activation and
memory to Thl, Tel, and Th17 cells compared to control lymph nodes. However, no
significant differences were found in systemic levels of any evaluated cytokines
between control plasma and plasma from patients bearing premalignant lesions.
This data indicates that, at the stage at which premalignant lesions become
detectable, a strong local inflammatory immune response, with no accompanying
immunosuppression} has been mounted.
While the data clearly indicates that the premalignant stage of HNSCC
development is associated with a strong inflammatory immune response, the role of
the response is still unclear. Classical thought would indicate that the observed
response is part of an anti-tumor immune reaction that, in the case of 4NQO-treated
mice, is unable to eliminate the dysplastic effects of ongoing carcinogen treatment.
However, it is also possible that the observed inflammatory response is partially
responsible for continued progression towards cancer. Further investigation into
the roles of these cells through models involving oncogenesis in IFN -y, IL-17 A, CD4,
or CDS knockout mice will serve to uncover the beneficial or detrimental effects of
each of the immune cell types during tumor development.

5.2 Complexity of HNSCC-Associated Immune Response
The classic description of immune escape involves downregulation of
immunogenic properties, the skewing of a type I response to a type II response, and
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an upregulation of multiple immune inhibitory factors, such as regulatory T cells
(2). Past research indicates that HNSCC follows this model in several ways,
including a downregulation of MHC class I molecules and B7 molecules, an
upregulation ofTh2 cytokines, and a large increase in peripheral and tumorinfiltrating Tregs (28, 143-145, 163, 164). The present study sought to further
investigate the locoregional immune alterations in established HNSCC using both a
mouse model of 4NQO-induced carcinogenesis and human samples. While we did
observe the expected increase in Treg cells in cervical lymph nodes of HNSCCbearing mice compared to control, there was also an increase in levels of
conventional T cells found in lymph nodes of HNSCC-bearing mice compared to
control. In addition, there was an unexpected increase in Thl cells in cervical lymph
nodes of HNSCC-bearing mice compared to control mice. Human tumor samples
had a similar increase in levels of IFN-y compared to normal/adjacent control tissue.
This data indicates that, contrary to past research, an inflammatory reaction
involving Thl cells continues in the setting of established HNSCC.

The Th1 reaction observed in mice with established HNSCC could have
several implications. It is conceivable that this response may represent an ongoing
attempt at an anti-tumor response whose effects are simply overwhelmed by the
multitude of other immune manipulative factors induced by the tumor. Conversely,
it is possible that this response, and the Th1 and Tcl response observed at the
premalignant stage, is tumor promoting. Though generally associated with an antitumor response, IFN-y expression and Thl cells have been linked to tumor

promotion in several studies, most notably in carcinogen-induced tumors of
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epithelial origin similar to 4NQO-induced or tobacco

smoking~induced

HNSCC

development (120, 121). Thirdly, the Thl and Tel response observed at the
premalignant stage may be representative of a beneficial immune response} while
the Thl and Tel response at the HNSCC stage may be representative ofa
detrimental immune response. In cervical lymph nodes of premalignant lesionbearing mice, there is a higher increase in the percentage of Tcl cells than Thl cells}
while HNSCC-bearing mice have a higher increase in the percentage ofThl cells
than Tcl cells. In addition, premalignant lesion-bearing mice have a much greater
percentage of Th17 cells compared to HNSCC-bearing mice. It is possible that the
Tel and Th 17 cells at the premalignant stage are working together in a concerted
effort to combat oncogenesis, while the shift towards Thl cells and decrease in Th17
cells with a simultaneous increase in Tregs represents a completely separate, prooncogenic immune reaction at the HNSCC stage.
Established HNSCC was found to be associated with an increase in both
Teonv cells and Tregs. Further analysis revealed that Teonv cells from HNSCCbearing mice have a reduced proliferative capacity compared to Teonv cells from
control mice, providing somewhat of an explanation for how these stimulatory cells
could co-exist with what was expected to be an immunosuppressive
microenvironment. In addition. analysis of the Treg cells showed that,
unexpectedly} Tregs from HNSCC-bearing miee suppress Tconv cells to a lesser
degree than Tregs from control mice . It will be important in the future to determine
any other role these Tregs may be playing in the HNSCC microenvironment, as they
appear to lose their primary function ofT cell suppression as the tumor progresses.
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5.3 Immunotherapy at the Premalignant Stage
The rationale for initiation of immunotherapy at the premalignant stage of
HNSCC development included the fact that oral lesions are identifiable at the
premalignant stage, premalignant lesions and HNSCC share overexpression of
common tumor antigens, and the hypothesis that the premalignant stage of HNSCC
development would not be associated with the systemic immunosuppression that
past studies identified in patients with HNSCC (136, 173, 180). Our data showing
that both mice and humans with premalignant lesions experience a local increase in
inflammatory immune mediators without any immunosuppression supported our
reasoning behind initiation of immunotherapy at this point. In this study,
premalignant lysate-pulsed dendritic cells were administered to mice bearing
premalignant lesions in an attempt to halt or even reverse the progression of these
lesions to HNSCC. Unexpectedly, lymphocytes from DCpm mice did not show any
specificity of reaction to premalignant or HNSCC lysate challenge. However, both
DCpm vaccination and vaccination with the control vaccine were associated with a
decrease in lesion burden compared to unvaccinated, 4NQO-treated controls.
Analysis of draining cervical lymph node cells from vaccinated mice revealed that
DCnt vaccination resulted in an early increase in levels of stimulatory immune
effectors compared to DCpm and 4NQO control mice, while DCpm vaccination
resulted in a delayed increase in levels of stimulatory immune effectors compared to
4NQO control mice. This data indicated that activated Des were capable of
generating a non-specific immune stimulatory response associated with improved
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clinical prognosis regardless of the whether the Des were pulsed with normal
tongue or premalignant antigens. With this large increase in the non-specific
immune stimulatory response in mind, it is important to evaluate levels of
additional possible contributory cells, such as N K cells, N KT cells, and yS T cells, to
the anti-tumor response in future studies.
Evaluation of dendritic cell maturation markers and cytokines revealed no
significant differences between dendritic cells pulsed with normal tongue
epithelium lysate or premalignant epithelium lysate, and evaluation of lymphocytes
from DCnt and DCpm mice revealed no specificity of response to normal tongue
epithelium lysate, premalignant epithelium lysate, or HNSCC lysate challenge.
However, DCpm vaccination was found to reduce lesion burden two weeks earlier
than Dent vaccination, and Dent vaccination was found to increase multiple
stimulatory immune effectors at the 4 week point, while DCpm vaccination was not
associated with an increase in these effectors until the 8 week point. Additional
research into the differing consequences of pulsing dendritic cells with normal
tongue epithelium lysate versus premalignant lesion lysate is necessary to
determine what is responsible for the differing responses to the two vaccines.
Tumor lysate is often used as a source of antigen for dendritic cell
vaccination because it allows sensitization to mUltiple potentially immunogenic
TAAs simultaneously, a method that is especially helpful when the most
immunogenic TAAs expressed by the tumor tissue have not yet been identified
(226-228). Premalignant lesion lysate was used for the antigenic source for pulsing
dendritic cells for vaccination because previous studies showed that both
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premalignant lesions and HNSCC overexpress several of the same tumor antigens,
though the immunogenicity of each individual antigen has not yet been determined
(136, 180). The current study showed that, contrary to expectations, vaccination
with premalignant lesion-lysate pulsed dendritic cells did not result in the
development of a specific immune response to premalignant or HNSCC epithelium.
It is possible that components of the lysate, aside from TAAs may block or even
J

suppress sensitization of Des to the intended TAAs (229,230). As such, future
experimentation using specific antigens} rather than premalignant tissue lysate, to
pulse dendritic cells prior to vaccine administration may result in the successful
development of a specific response with increased clinical benefit.

5.4 Closing Remarks
The current study presented the evaluation of immune responses to the
development of HNSCC in carcinogen-treated mice and humans. Experimentation
revealed that the premalignant stage is associated with a rise in inflammatory
immune effectors without immunosuppression. while established HNSCC is
associated with a seemingly contradictory rise in both immunosuppressive and
immunostimulatory populations. The genuine roles of the evaluated immune
effectors have yet to be established; future experimentation involving carcinogentreatment of mice lacking expression of these individual cell populations is
necessary to determine the anti-tumor versus pro-tumorigenic functions of these
populations. The elucidation of these links will provide much-needed information
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for the tailoring of future immune therapies aimed at combatting or preventing the
development of HNSCC.
The current study also evaluated the feasibility of initiating immunotherapy
at the premalignant stage of HNSCC development} thus avoiding the obstacle of
systemic immunosuppression seen in established HNSCC} specifically through the
use of premalignant antigens in a dendritic cell vaccine. Both the experimental
DCpm vaccine and the control DCnt vaccine resulted in clinical benefit to
carcinogen-treated mice, even without the development of a specific response to
premalignant or HNSCC antigens} a result that is both unexpected and promising.
Future investigation involving optimization of dendritic cell preparation. perhaps
using specific TAAs as an antigen source, will allow for more efficient development
of treatments that have an increased opportunity of being clinically effective and

may eventually be used in the clinic to combat this notoriously highly aggressive
and tenacious malignancy.
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